AUTHOR INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page number.
Articles appearing in AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.
Page references to Supplement 1 (June 1998) are preceded by S1:

Abbate, M., 453
Abrinko, P., 766
Adams, M. B., 928
Adler, S., 901
Ahern, K., 263, 2:E3
Ahuja, T. S., 127
Aikawa, A., 301
Al-Awwa, I. A., S1:15
Albitar, S., 4:E3
Alfrey, E. J., 142
Alfurayh, O., 706
Allgren, R. L., 674
Al Meshari, K., 706
Amini, S. B., 593
Anders, S., 860
Anderson, J., 81
Andrassy, K., 978
Aperia, A., 2:xliii
Appel, R. G., 28, 375
Arakawa, M., 666
Araki, H., 3:E4
Armelloni, S., 435
Ashby, M., 224
Asolati, M., 509
Aspinwall, R., 1038
Atkins, R. C., 1:xlv
Auerbach, M., 81

Baboolal, K., 971
Badenas, C., 1038
Bagon, J. A., 756
Banfi, G., 681
Bansal, V. K., 135
Barbod, A., 5:E3
Bartholomew, A. M., 509
Bates, E. R., 674
Batlle, D., 19
Baumann, C., 234
Beaud, J.-M., 830
Beazley, R. M., 853
Beezhold, D. H., 1007
Behrend, M., 234
Beirão, I., 940
Benedetti, E., 509
Bengal, R. J., 687
Benigni, A., 453
Bergström, J., 1050
Berl, T., 1028
Berland, Y., 67
Bernardini, J., 101
Beto, J. A., 135
Biggerstaff, S., 947
Blake, P. G., 242
Bleyer, A. J., 28
Block, G. A., 607
Bolton, W. K., 786
Bosc, J.-Y., 74, 87
Bosch, J. P., 618
Bourgeon, B., 4:E3
Bouthot, B. A., 920
Boyle, J. A., 780
Bradfield, E., 242
Brady, J. P., 35
Braga, M., 479
Brathwaite, M., 250
Brenner, B. M., 161
Brezina, M., 647
Briefel, G., 81
Briggs, W. A., 213
Brinker, K. R., 631
Bro, S., 257
Brouilette, J., 890
Brown, H. G., 329
Brown, M. A., 308
Brunet, P., 67
Brunkhorst, R., 234
Bruzzi, I., 453
Burns, G. C., 719
Burrows-Hudson, S., 5:E5, 818

Callizo, J., 5:E3
Camacho, J. A., 1038
Campbell, M. K., 473
Canaud, B., 74, 87
Cannon, C. L., 710
Cantarovich, D., 473, S1:26
Capitanio, M., 453
Cappellari, A., 350
Caruana, R., 584
Caswell, N., 662
Catto, G. R. D., 473
Cebul, R. D., 593
Cendoroglo, M., 273
Chagnac, A., 539
Chan, J. K., 283
Chan, K-w., 5:E4
Chan, T-m., 5:E4
Chau, K. F., 986
Chen, A., 443
Chen, L.-M., 638
Chen, R., 28
Cheng, Y. L., 986
Chertow, G. M., 545
Cheung, J. Y., 698
Cho, S. I., 853
Choi, K. S., 986
Choi, M. J., 213
Chou, W.-Y., 443
Chubachi, A., 336
Chugh, K. S., 3:lvii
Churg, J., 559
Cohen, A. H., 513
Cohen, A. T., 227
Cohl, E., 491
Cole, M. J., 647
Collado-Seidel, V., 324
Collins, J. F., 1011
Corna, D., 453
Crosson, A. W., 6:E5

D'Agostino, R. B., Jr., 28
D'Amico, G., 435
Danielson, B., 1:E3
Darnell, A., 1038
Daugirdas, J. T., 135
Davison, A. M., 227
Deiss, W., Jr., 127
Delcroix, C., 473
De Luca, L. G., 521
De Medina, M., 224
Demetris, A. J., S1:7
Demko, T. M., 698
De Muylder, X., 756
DeOreo, P. B., 593
De Vecchi, A. F., 479
De Vriese, A. S., 108
Dharnidharka, V. R., 710
Dheenan, S., 624
Dignant-George, F., 67
Dixit, V., 647
Dobson, A., 502
Donadelli, R., 453
Donck, J., 218
Dou, L., 67
Douzdjian, V., 794
Dreisbach, A. B., 1007
Droz, D., 940
Dunn, T., 509
Dunne, E., 263, 2:E3
Dunst, R., 116

Edward, N., 473
Eknoyan, G., 2:xlvi
Emonds, M.-P., 218
Emoto, M., 655
Endo, T., 356
Epstein, F. H., 19
Epstein, M., 743
Ericsson, F., 803
Esparaz, D. Y., 19
Estacio, R. O., 947
Estivill, X., 1038
Eto, T., 991
Evans, C., 971

Fabrizi, F., 647
Fahmy, H. I., 853
Farach-Carson, M. C., 729
Farmer, C., 584
Farrell, T., 308
Federman, M., 6:E5
Feehally, J., 313
Feest, T. G., 12
Feldt-Rasmussen, B., 257
Fernández-Juárez, G., 701
Ferrara, D., 794
Fervenza, F. C., 142
Fijimoto, S., 991
Finkel, K. W., 1:E2, 2:E2, 3:E2, 5:E2, 6:E2
Fioretto, P., 293
First, M. R., 928, S1:15, S1:40
Fish, A. J., 293
Fivush, B. A., 329
Flanigan, M. J., 495
Fogazzi, G. B., 350
Fogo, A., 155, 1:E1, 2:E1, 3:E1, 723, 890, 5:E1, 1058, 6:E1
Fogué, L., 701
Fontenaille, C., 473
Fornasieri, A., 435
Fraser, V. J., 848
Frederiks, P., 962
Freund, L., 5:E5, 818
Frye, R. F., 1019
Fukushima, K., 932
Fukushima, T., 6:E4
Fung, J. J., S1:7

Gaber, A. O., S1:40, S1:47
Gaber, L. W., S1:19
Gafter, U., 539
Gallen, I. W., 19
Garcia, C., 5:E3
Garred, L. J., 74
Gejyo, F., 666
Genin, R., 4:E3
Genter, F. C., 674
Gerosa, S., 647
Gitnick, G., 647
Gleed, R. D., 502
Göbel, U., 860
Goodenow, M. M., 418
Goodship, T. H. J., 884
Gopalakrishnakone, P., 6:xlviii
Goral, S., 890, 1058
Goutcher, E., 227
Grande, J. P., 360, 687
Griffin, M. D., 360
Gritter, N. J., 1058
Groff, J. A., 698
Gröne, H.-J., 1044
Grubb, B. P., 624
Grünfeld, J.-P., 940
Gruzman, C., 539
Guh, J.-Y., 638
Guijarro, C., 190
Guimarães, S., 940
Guimarães, S. M., 940
Gura, V., 513
Guttmann, R. D., S1:1, S1:40

Haas, M., 550
Haley, W., 584
Hall, F., 81
Hamai, K., 336
Hamel, M. B., 545
Handberg, J., 257
Hänsch, G. M., 978
Hara, K., 809
Hariharan, S., 928, S1:15
Harris, H. W., 710
Harris, K. P. G., 313
Harris, P. C., 1038
Hasbargen, J. A., 35
Hasegawa, A., 301
Hayashi, I., 301
Heimbürger, O., 1050
Held, P. J., 997
Henderson, I. S., 473
Hendrickson, T., 1007
Henrich, W. L., 624
Herman, M., 539
Herrera-Acosta, J., 896
Herzenberg, A. M., 521
Hess, G., 218, 224
Hibi, I., 93
Higashi, T., 602
Hill, M., 224
Hillebrand, G. F., 324
Hino, S., 932
Hirschberg, R., 901
Hisanaga, S., 991
Hishida, A., 1032
Ho, Y.-S., 443
Holden, J. K., 521
Holley, J. L., 574, 662
Holub, B. J., 55
Horii, A., 356
Horn, R., 890
Hou, S., 766
Howlett, T. A., 313
Huang, T.-P., 694
Hulbert-Shearon, T. E., 607
Hull, A. R., 863
Hunley, T. E., 155

Ianez, L. E., 3:E3
Idelson, B. A., 853
Iijima, K., 774
Imai, H., 336
Indrikovs, A. J., 127
Ing, T. S., 135, 986
Inoue, T., 655
Iskandar, S., 375
Iwasaka, T., 602

Jaber, B. L., 273
Jacquesson, M., 4:E3
Jeffers, B. W., 947
Jeffers, L. J., 224
Jin, D. K., 293
Jindal, K. K., 49
Johnson, C. P., 928
Johnson, D., 947
Jones, C. A., 997
Jones, C. H., 227
Joy, M. S., 1019

Kaizu, Y., 93
Kalantar-Zadeh, K., 263, 2:E3
Kamata, K., 356
Kaplan, N. M., 864
Karasawa, R., 666
Kasiske, B. L., 149, 190, 954
Kataoka, N., 6:E4
Kawamura, M., 991
Kawano, M., 3:E4
Keane, W. F., 190
Kettritz, R., 860
Kettritz, U., 860
Khan, I. H., 473
Kiberd, B. A., 49, 364
Kim, Y., 190, 293
Kimmel, P. L., 283
Kimura, H., 666
Kimura, M., 93
Kjellstrand, C. M., 803
Klahr, S., 171
Kleiner, M., 263, 2:E3
Kleinman, K. S., 513
Klomburg, S., 369
Klotman, P. E., 719
Kobayashi, M., 301
Kobayashi, N., 356
Kobayashi, Y., 336
Koene, R. A. P., 1, 473
Kohnen, R., 324
Koide, M., 774
Kojima, S., 41, 856
Komatsuda, A., 336
Koni, I., 3:E4
Koo, L. C., 62
Korzets, A., 539

Kosala, H., 218
Koslowe, R., 263, 2:E3
Kramer, M. D., 978
Krisher, J., 584
Krivitski, N. M., 502
Kruytzer, M., 962
Kuhlmann, U., 116
Kumagai, H., 93
Kumano, K., 356
Kuramochi, M., 41, 856
Kurnik, B. R. C., 674
Kurosawa, K., 6:E3
Kurtzman, N. A., 866

Lafayette, R. A., 142
Lafontaine, J.-J., 756
Lai, Y.-H., 638
Lakatua, J. D. A., 954
Lameire, N. H., 108
Landsberg, L., 19
Lau, J. Y. N., 920
Lavre, J., 536
Lawrence, I. G., 313
Leavey, S. F., 997
Leblanc, M., 74, 87
Leclerq, B., 224
Lee, W.-H., 443
Lemann, J., Jr., 369
Lenz, T., 1044
Leray-Moragues, H., 87
Levey, A. S., 920
Levin, N. W., 607
Levine, D. Z., 131
Lew, S. Q., 618
Li, C. S., 986
Li, M., 435
Liaño, F., 701
Lin, K.-P., 694
Lin, Y.-F., 443
Lindholm, B., 1050
Lindsay, R. M., 242
Lipschutz, J. H., 383
Lo, A., 329
Lo, K-y., 713
Lobato, L., 940
Longmaid, H. E., 6:E5
Louis, T. A., 954
Low, P. A., 687
Luft, F. C., 263, 2:E3, 860
Luke, R. G., 780

Ma, J. Z., 954
Mabuchi, H., 3:E4
McAdams, A. J., 427
Maccario, M., 479, 681
McClellan, W. M., 584
MacDonald, A., 364
McDonald, F., 3:lxiv
MacDonnell, R. C., Jr., 155
McFarling, E., 947
MacGibbon, D., 502
McGinley, M., 81
McGuirl, K., 662
Mackenzie, H. S., 161
McKenzie, J. K., 12
MacLeod, A. M., 473
Magil, A. B., 521
Mailliard, M. E., 366
Mak, S.-K., 713
Malek, P., 242
Marcus, R. G., 491
Maroni, B. J., 185
Marshall, M. R., 1011
Martens, J., 756
Martin, B., 242
Martin, P., 647
Martinez-Maldonado, M., 1048
Martínez-San-Millán, J., 701
Martinez-Vea, A., 5:E3
Marumo, R., 6:E3
Maruyama, K., 809
Massengill, S. F., 418
Massy, Z. A., 190
Mathew, A., 848
Matsubara, M., 6:E3
Matzke, G. R., 1019
Mauer, M., 293
Maurice, F., 87
Melby, J. C., 853
Mesler, D. E., 853
Mettang, T., 116
Miller, K. L., 698
Minamoto, M., 3:E4
Mion, C., 74
Mishkin, G. J., 618
Misra, M., 1050
Mitch, W. E., 185
Mitchell, J. H., 631
Mitty, H. A., 533
Miura, A. B., 336
Miura, I., 336
Miyagi, M., 301
Miyaji, K., 93
Miyazaki, R., 666
Mizuiri, S., 301
Mohanty, L. B., 121
Molina, J. C., 5:E3
Molony, D. A., 133, 1:E2, 2:E2, 3:E2, 5:E2, 6:E2
Moore, G. E., 631
Moore, L. W., S1:31, S1:40, S1:47
Moore, R. H., 971
Morcos, M., 978
Morii, H., 655
Morita, A., 655
Morita, T., 559
Moroni, G., 681
Morrissey, J., 171
Moss, A. H., 12, 464, 868
Mousa, M., 647
Murakami, K., 932
Murakami, R., 774
Muramoto, H., 3:E4
Murthy, B. V. R., 920

Nadeau, K., 710
Nadler, S., 835
Nagase, M., 1032
Naito, I., 6:E4
Nakamura, H., 774
Nanbu, A., 809
Nassar, G. M., 121
Natov, S. N., 920
Nelson, M., 263, 2:E3
Neu, A. M., 329
Newman, N., 1007
Newstead, C. G., 227
Nickander, K. K., 687
Nieuwhof, C., 962
Niles, J., 341
Nishimura, M., 809
Nishiue, T., 602
Nishizawa, Y., 655
Noël, L.-H., 940
Nolph, K. D., 1050
Nomura, S., 6:E4
Nonomura, A., 3:E4

Obasi, E. O., 550
Obialo, C. I., 250
Obrador, G. T., 398
Odar-Cederlöf, I., 803
O'Donnell, M. P., 190
Oertel, W. H., 324
Ogburn, M. R., 55
Ogi, M., 41, 856
Ohara, T., 301
Ohtani, H., 336
Ohtsuka, K., 809
Oka, M., 1032
Okada, M., 932
Okubo, M., 356
Okundaye, I., 766
Oldroyd, S., 453
Olgaard, K., 257
Oliver, J. A., 5:E3
Ori, Y., 539
Orofino, L., 701
Ortuño, J., 701
Osawa, G., 6:E4

Painter, P. L., 631
Palevsky, P. M., 1019
Papadimitriou, M., 473
Papp, P., 509
Park, L., 835
Park, Y-S., 190
Pascual, J., 701
Peddi, V. R., 928
Pedro, P., 121
Pennell, J. P., 224
Peralta, C., 5:E3
Pereira, B. J. G., 273, 398, 920

Perez, G. O., 224
Petersen, J., 142
Phan, L. T., 1065
Philbrick, D. J., 55
Piraino, B., 101
Pollak, R., 509
Ponticelli, C., 479, 681
Port, F. K., 607, 997
Porush, J. G., 177
Posen, G., 242
Potti, A., 1:E3
Pouletty, P., S1:40
Preisig, P., 818, 5:E5
Price, D. E., 313

Quaglini, S., 681
Qunibi, W., 706

Racusen, L. C., 329
Radsak, M., 978
Rajaraman, S., 127
Ramirez, S. B., 341
Rasmussen, R. A., 257
Ray, N. F., 283
Raysay, C., 473
Reddy, K. R., 224
Reichert, L. J. M., 1
Remmers, R. E., 121
Remuzzi, G., 197, 453
Ribera, A., 4:E3
Richards, K., 81
Richardson, D., 227
Ridall, A. L., 729
Ritz, E., 473
Riu, S., 5:E3
Riviere, J.-P., 4:E3
Rivolta, E., 350
Rizvi, S. A. H., 4:xlv
Robbrecht, D. L., 108
Robertson, G. L., 19
Robinson, T., 250
Rodby, R. A., 345
Roland, J., 978
Romão, J. E., Jr., 3:E3
Rosa, R. M., 19
Rosen, S., 341, 710
Ross, E. A., 62
Rothstein, M., 848
Rovin, B. H., 1065
Roza, A. M., 928
Ruthazer, R., 920
Rydel, J. J., 345

Sabbaga, E., 3:E3
Sabeel, A., 706
Šabovič, M., 536
Saito, T., 6:E3
Sakai, K., 301
Saldanha, L. B., 3:E3
Sampol, J., 67
Samtleben, W., 324
Santamaria, P., 1011
Sato, H., 6:E3
Sato, K., 356
Sattin, R. D., 1048
Saudan, P. J., 308
Savin, V. J., 928
Sayegh, M. H., 320
Scalamogna, A., 479
Scheel, P. J., Jr., 213
Schelstraete, R., 218
Scherberich, J. E., 1044
Schiff, E. R., 224
Schindler, R., 234
Schlüter, V., 224
Schmid, C. H., 920
Schmidt, R., 1044
Schneider, W., 860
Schrier, R. W., 947
Schroeder, T. J., S1:31, S1:40, S1:47
Sehgal, A. R., 593
Seiler, S., 848
Sekkarie, M. A., 464
Sen, K., 1:E3
Serveaux, J.-P., 4:E3
Serveaux, M.-O., 4:E3
Sessa, A., 435
Setijoso, E., 218
Sexton, C. W., 375
Shappell, S., 723
Shek, C. C., 986
Sheng, L., 218
Sheu, L.-F., 443
Shoji, T., 655
Siegler, M., 12
Silberzweig, J. E., 533
Silver, M. R., 593
Silvestri, G., 794
Singer, I., 743
Singer, M. E., 593
Sitprija, V., 6:xlviii
Sivak, S. L., 719
Sklar, A. H., 1007
Sleasman, J. W., 418
Smith, S., 662
Smith, W., 121
Smith, Y., 509
Snow, R. J., 593
Solomon, R. J., 674
Soma, J., 6:E3
Somers, M. J. G., 341
Soucie, J. M., 584
Soulillou, J.-P., S1:1, S1:26, S1:40
Soumillion, A., 218
Starzl, T. E., S1:7
Stein, A., 884
Stocking, C. B., 12
Strawderman, R. L., 997
Stray-Gundersen, J., 631
Sundaram, S., 273
Suzuki, H., 1032
Suzuki, S., 666
Suzuki, Y., 666

Tabata, T., 655
Taguma, Y., 6:E3
Takahashi, H., 55, 809
Takemura, T., 932
Takeuchi, Y., 356
Tamura, K., 602
Tan, P. H., 513
Tanaka, H., 6:E4
Tanaka, I., 6:E4
Tanaka, R., 774
Tanaka, S., 655
Tanegashima, M., 301
Tarelli, L. T., 435
Tarng, D.-C., 694
Tato, A. M., 701
Tazzari, S., 435
Teitelbaum, I., 1028
Telford, J. J., 521
Testa, A., 830
Tey, S., 533
Thaler, S. M., 1028
Thamer, M., 283
Theodorsson, E., 803
Tierney, M., 835
Todo, S., S1:7
Tokura, T., 6:E4
Tomobe, K., 55
Torra, R., 1038
Torres, V. E., 687
Trenkwalder, C., 324
Trey, G., 6:E5
Tsakiris, D., 473
Tsevat, J., 545
Tsuji, H., 602
Tsukamoto, Y., 356
Tulchinsky, M., 698
Twardowski, Z. J., 841

Uhthoff, T., 835
Uribarri, J., 491

Valli, G., 350
Van Breda Vriesman, P. J. C., 962
Van den Dorpel, M. A., 149
Van Hamersvelt, H. W., 473
Vanholder, R. C., 108
Vanrenterghem, Y., 218
Van Roost, G., 756
Vassalotti, J. A., 283
Vats, A., 293
Vaussenat, F., 87
Velasco, A., 127
Velasquez, M. T., 618
Vella, J. P., 320
Velosa, J. A., 360
Venkatesan, J., 624

Vernaeve, H., 756
Verslype, C., 218
Vo, T., 74
Vogelaers, D. P., 108
Von Albertini, B., 618
Von Mühlendahl, K. E., 369
Vujkovac, B., 536

Wahab, A., 81
Wakui, H., 336
Walczak, D. A., 509
Walls, J., 313, 884
Wang, J.-Y., 443
Wang, T., 1050
Washington, A. W., 509
Weening, J. J., 5:1
Weimar, W., 149
Weinstein, T., 539
Weisberg, L. S., 674
West, C. K., 427
Wetzels, J. F. M., 1
Widyastuti, A., 218
Wiesner, R. H., 360
Will, E. J., 227
Williams, M. E., 6:E5
Winchester, J., 81
Winston, J. A., 533
Woeltje, K. F., 848
Wong, A. K. M., 713
Wong, F. K. M., 986
Wong, P-n., 713
Wörner, I., 978
Wrenger, E., 234 Yadin, O., 513
Yagi, K., 932
Yajima, I., 602
Yamada, M., 3:E4
Yamamoto, T., 559, 1032
Yamamoto, Y., 991
Yamashita, M., 655
Yang, C.-Y., 638
Yang, J.-M., 638
Yap, S. H., 218
Yared, A., 155
Yoneyama, T., 93
Yoshihara, S., 1032
Yoshikawa, H., 301
Yoshikawa, N., 774
Yoshimura, M., 809
Yoshioka, K., 932
Yoshitomi, Y., 856
Young, J. B., 19

Zamore, E., 234
Zawadzki, J., 527
Zevin, D., 539
Zimmermann, F., 978
Zoja, C., 453

SUBJECT INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.
Articles appearing in AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.
Page references to Supplement 1 (June 1998) are preceded by S1:

Access recirculation, HD
  dialyzer blood flow and, 502-508
  with internal jugular vein TwinCath, 87-92
  measured with HDM, 242-249
Accidental hypothermia of cold water immersion, ARF in, 856-859
ACE, *see* Angiotensin-converting enzyme
ACEIs, *see* Angiotensin-converting enzyme inhibitor(s)
Acidosis
  immune-related distal tubular, permeability defect with HCO_3 leak and, 527-532
  metabolic, *see* Metabolic acidosis in ESRD patients on CAPD and/or HD
Acquired adult thymic tolerance to transplantation, 203-207
Acquired immunodeficiency syndrome nephropathy, *see* HIV infection; HIVAN
Acute hypotension during chronic HD, enhanced NO production and, 809-817
Acute interstitial nephritis with rifampicin-associated ARF, 113
Acute kidney transplant rejection
  Banff classification of, S1:19-25, S1:31-39
  clinical trials of, *see* Clinical trials of acute kidney transplant rejection
  diagnosis of, *see* Acute kidney transplant rejection, diagnosis of
  recovery of renal function following treatment of, S1: 47-59
Acute kidney transplant rejection, diagnosis of
  questionnaire on, S1:26-30
  see also Renal biopsy, renal allograft rejection diagnosis and
Acute renal failure (ARF), 3:lvii
  in accidental hypothermia of cold water immersion, 856-859
  anuric, complicating PSC, OLT for, 360-363
  cost-effective dialysis for, 545-549
  DA-1 agonists for, 748-755
  due to ciprofloxacin overdose, apoptosis in, 710-712
  fever, anasarca, thrombocytopenia and, 890-895
  IGF system in, 913-915
  MOF with, *see* Multiorgan failure, ARF with
  radiocontrast-induced, 674-680
  rhabdomyolysis, snake bite and, 6:xlviii-l
  rifampicin-associated, 108-115
Acute tubular necrosis (ATN)
  ciprofloxacin overdose-associated ARF and, 710-712
  rifampicin-associated ARF and, 111
Adequacy
  of CAPD and CCPD, compliance and, 101-107
  see also Adequacy of HD for ESRD
Adequacy of HD for ESRD
  barriers to, 593-601

blood sample to determine, *see* Blood samples, HD adequacy for ESRD determined with
HCFA report on, 584-592
IDWG and, 830-834
in nondiabetic elderly patients, 485-486
see also Kt/V on HD; On-line urea monitoring
ADH (antidiuretic hormone), *see* Vasopressin
Adolescents, NS in, 155-160
ADPKD, *see* Autosomal dominant polycystic kidney disease
Adrenal vein sampling in posttransplantation HTN due to primary hyperaldosteronism, 853-855
Adrenaline, plasma, in DN, 44-46
Adult thymic tolerance to transplantation, acquired, 203-207
Advance care planning (advance directives), dialysis discontinuation and, 464-472, 871-872
Adverse drug reactions between fluvoxamine, nefazodone, and CsA, 320-323
Adverse effects of urokinase, 844
African Americans, *see* Race and ethnicity
Age
of AmB therapy patients, 781
of ARF patients, 111-113, 228, 229
of bilateral atherosclerotic renovascular disease patients, 972, 974
of brachial plexus compression, 696
of childhood IgAN patients, 776
of CVVH and CVVHD patients, vancomycin clearance and, 1021
of DN patients, 42, 94, 303, 668, 670
of FAP type I patients, 941
gestational, *see* Age, gestational
of GN patients, 352, 515
of idiopathic MN patients, 2-4
of MLN patients, 682
of NIDDM patients, 949, 950
of NS patients, 933, 936
of RCIN patients, 676
restricted dietary K effects on BP and Na excretion and, 19-27
of RRT patients, outcomes and, 475; *see also* Age of ESRD patients on CAPD and/or HD; Age of renal transplant recipients
Age, gestational
and gestational HTN, 310
of infants born to ESRD mothers on HD, 760, 769-772
Age of ESRD patients on CAPD and/or HD, 587
AIDS patients, vascular access thrombosis and survival and, 251
BP control and, 620
on chronic HD, 37, 95, 96, 604, 610-612, 992-993
compliance and, 103
HD adequacy and, 595, 597
HH and, 625
hypertensive ESRD, 30, 31
IDWG and, 831
malnutrition and, 265, 267, 268, 998, 1000, 1001
and PD, sexual dysfunction and, 314-316
plasma leptin levels and, 660
of pregnant patients, 760
and on rHuEPO therapy, iron dextran for, 83, 837
TB and, 849
and urokinase to restore CVC patency, 843
weekly Cr clearance, Kt/V_{urea} and, 496
withdrawal and/or withholding of dialysis and, 467
Age of renal transplant recipients
acute rejection and, S1:34, S1:51-53, S1:55, S1:57
drug use concomitant with CsA therapy and, 285
mentally retarded patients, 510
recurrent and de novo renal diseases and, 929
AIDS (acquired immunodeficiency syndrome), *see* HIV infection; HIVAN
Alanine aminotransferase (ALT; serum glutamate pyruvate transaminase)
in HCV infection, 647-654, 922, 923
in HGV infection, 221
Albumin
in CVVH and CVVHD patients, vancomycin clearance and, 1021
in HCV-infected renal transplant candidates, 922; *see also* Albumin in ESRD patients on CAPD and/or HD
see also Albuminuria; Serum albumin
Albumin in ESRD patients on CAPD and/or HD, 587
Ca ketoglutarate and Ca carbonate effects on, 260
on chronic HD, 610-612, 993, 994
effects of metabolic acidosis correction on, 35-40
in elderly nondiabetic patients, 484
HTN control and, 621
IDWG and, 831, 832
TB and, 850
TIBC, malnutrition and, 265, 268
vascular access thrombosis and survival and, 251
Albuminuria
lovastatin effects on, in PA nephrosis, 190-194
as predictor of diabetic retinopathy in Hispanics with NIDDM, 947-953
see also Microalbuminuria; Proteinuria
Aldosterone, DA receptor stimulation effects on, 745
Alkaline phosphatase (ALP)
HTN control and, 621
in rickets, 373
Alpha3beta1 ($\alpha 3\beta 1$) in renal development, 386, 390-391
Alpha8beta1 ($\alpha 8\beta 1$) in renal development, 386, 390-391
Alpha (α)-tocopherol (vitamin E), renal, sex and effects of, on PKD, 687-693
Alport's syndrome (AS), autosomal recessive, molecular genetic and immunohistochemical studies of, 6:E4
ALT, *see* Alanine aminotransferase
AmB (amphotericin B), nephrotoxicity of, 780-785
Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis
Amphotericin B (AmB), nephrotoxicity of, 780-785
Amyloid polyneuropathy type I, familial, distribution and characterization of amyloid deposits in, 940-946
Amyloidosis, cardiac β_2-m, in long-term HD, 3:E4
Anaritide, plasma, in RCIN, 677
Anasarca, thrombocytopenia, fever, and ARF, 890-895
ANCAs, *see* Antineutrophil cytoplasmic antibodies
Anemia
rifampicin-associated hemolytic, 108-115
see also Anemia in ESRD patients on HD
Anemia in ESRD patients on HD
and heart rate variability in chronic HD patients, 602-606

in pregnant women, 769, 772
with RLS, 324-328
see also Recombinant human erythropoietin for ESRD patients on CAPD and/or HD
Anergy, TB and, in HD patients, 848-852
Aneurysm, "true" mycotic renal artery graft, 1:E3
Angiodysplasias, colonic, in ESRD patients on HD, tranexamic acid for GI bleeding due to, 536-538
Angioplasty, percutaneous transluminal renal, for transplant RAS, 146
Angiotensin II (AngII)
inhibitors of, effects of, on ATS GN, 453-463
NPY, volume-induced HTN on HD and, 803-808
see also Angiotensin II, gene expression and; Angiotensin II receptor antagonists
Angiotensin II (AngII), gene expression and, 171-176
of NF-κB, 173-174
of PAI-1, 173
of TFG-β1, 172-173
of TNF-α, 174
Angiotensin II (AngII) receptor antagonists, effects of, on chronic nephropathy progression, 167
Angiotensin-converting enzyme (ACE)
renal, immunohistochemical localization of, in DN, 301-307
see also Angiotensin-converting enzyme inhibitor(s); Polymorphism, ACE gene
Angiotensin-converting enzyme inhibitor(s) (ACEIs)
captopril effects on dexamethasone-induced proteinuria, 448
for HIVAN, 719-722
for hypertensive CRF, 177-184
preventing and/or retarding progression of DN with, 49-54, 165-167
ANN (artificial neural network), prediction of equilibrated postdialysis BUN with, in high-flux HD, 638-646
ANPs, *see* Atrial natriuretic peptides
Antibodies
antilymphocyte, recovery of renal function following acute rejection therapy with, S1:47-59
GN induced by anti-Thy-1, mesangiolysis due to, 561-563
HCV, in HCV-infected renal transplant candidates, 922-923
see also Antineutrophil cytoplasmic antibodies
Antidepressant(s), nefazodone and fluvoxamine as, adverse drug reactions between CsA and, 320-323
Antidiuretic hormone, *see* Vasopressin
Antifungal therapy with AmB, nephrotoxicity of, 780-785
Anti-glomerular basement membrane (GBM) nephritis with DN, 127-130
Antihyperlipidemic therapy to retard chronic DN progression, 168
Antihypertensive therapy
guidelines of JNC sixth report on, 864-867
see also specific antihypertensive therapies; for example: Angiotensin-converting enzyme inhibitor(s)
Antilymphocyte antibodies, recovery of renal function following acute rejection therapy with, S1:47-59
Antineutrophil cytoplasmic antibodies (ANCAs)
IgA, in IgAN, 341-344
see also Antineutrophil cytoplasmic antibodies, systemic vasculitis and; Myeloperoxidase antineutrophil cytoplasmic antibodies
Antineutrophil cytoplasmic antibodies (ANCAs), systemic vasculitis and, 5:l-lii
ANCA-negative central nervous system vasculitis with Goodpasture's syndrome, 345-349
ANCAs to PMN elastase enhancing elastase activity in, 978-985
see also Wegener's granulomatosis, ANCAs in
Antirejection therapy, *see* Immunosuppression
Anti-Thy-1 antibody-induced glomerulonephritis (GN), mesangiolysis due to, 561-563
Antithymocyte serum glomerulonephritis (ATS GN), effects of angiotensin II inhibitors on, 453-463
Anuria, ARF with, complicating PSC, OLT for, 360-363
APACHE II score, and survival with ARF and MOF, 228-229
Apolipoprotein(s), serum, in renal transplant recipients, probucol effects on, 356-359
Apolipoprotein E4 polymorphism, DN risk reduced by, in NIDDM, 666-673
Apoptosis in ciprofloxacin overdose-induced ARF, 710-712
ARF, *see* Acute renal failure
Arteritis
Takayasu's, renovascular HTN and, 3:lix
temporal, renal failure in, 1044-1047
Arthritis, rheumatoid, erythema elevatum diutinum, POEMS syndrome, steroid-dependent DM and, as extramedullary manifestations of plasma cell dyscrasia, 4:E3
Artificial neural network (ANN), prediction of equilibrated postdialysis BUN by, in high-flux HD, 638-646
AS (Alport's syndrome), autosomal recessive, molecular genetic and immunohistochemical studies of, 6:E4
Aspartate aminotransferase (AST), plasma, in gestational HTN, 310
Aspergillosis, AmB for, 782-784
AST (aspartate aminotransferase), plasma, in gestational HTN, 310
Atherosclerosis, as risk factor for hypertensive ESRD, 28-34
Atherosclerotic renovascular disease, medically treated severe bilateral, incidence of ESRD with, 971-977
Atlas of renal pathology, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
ATN, *see* Acute tubular necrosis
Atrial natriuretic peptides (ANPs)
plasma, effects of orthostatic hypotension on, in DN, 41-48
in prevention of RCIN 674-680
ATS GN (antithymocyte serum glomerulonephritis), angiotensin II inhibitor effects on, 453-463
Autonomic dysfunction, and heart rate variability in ESRD patients on chronic HD, 602-606
Autosomal dominant polycystic kidney disease (ADPKD)
as primary diagnosis in pregnant ESRD patients on HD, 757
TSC and, 1038-1043
Autosomal recessive Alport's syndrome (AS), molecular genetic and immunohistochemical studies of, 6:E4

B-cell MALT (mucosa-associated lymphoid tissue type) lymphoma, low-grade, crescentic IgAN with, chlorambucil for, 713-718
Banff classification of acute kidney transplant rejection, S1:19-25, S1:31-39
bDNA (branched DNA) signal amplification assay of HCV infection in chronic HD patients, 647-654
"Beer potomania" in non-beer drinkers, hyponatremia and, 1028-1031
Berger's disease, *see* IgA nephropathy
Beta$_2$-microglobulin, *see* β_2-Microglobulin; β_2-Microglobulin amyloidosis
BF, *see* Blood flow
BF-2 in renal development, 386, 389
Biases of PCPs, role of, in delayed referral of CRF patients to nephrologist and, 402
Bicarbonate, *see* HCO_3
Bilateral atherosclerotic renovascular disease, medically treated severe, incidence of ESRD with, 971-977
Bilirubin, total, in CVVH and CVVHD patients, vancomycin clearance and, 1021
Biochemical findings
  on renal function, RRT initiation and, 408-410
  on uremic RLS patients, 324-328
  see also specific biochemical data
Biocompatible membrane, postdialysis fatigue and, 1007-1010
Biopsy, *see* Renal biopsy
Biostat 1000 dialysate-based quantification of HD, 1011-1018
Birth weight of infants born to ESRD mothers on HD, 760, 769-772
Black Americans, *see* Race and ethnicity
Bleeding, *see* Hemorrhages
Blood flow (BF)
  dialyzer, dilution techniques in measurement of, 502-508
  in internal jugular vein TwinCath, 87-92
  renal, DA-1 agonist effects on, 743, 745, 746, 748-752
Blood glucose in DN, 44-46
Blood pressure (BP)
  in ATS GN, effects of angiotensin II inhibitors on, 456
  in bilateral atherosclerotic renovascular disease, 972, 974
  in childhood IgAN, 776
  DA receptor stimulation effects on, 745
  in IDDM, 294
  in NIDDM, 949
  in RCIN, 676
  restricted dietary K effects on, 19-27
  see also Blood pressure on HD for ESRD; Hypertension; Hypotension
Blood pressure (BP) on HD for ESRD
  chronic HD, 37, 95, 604
  on high-efficiency and/or conventional HD, 618-623
  IDWG and, 831, 832
  in pregnant patients, 758, 771
  stationary cycling effects on, 631-637
Blood samples, HD adequacy for ESRD determined with, 135-141
  Daugirdas blood-based measurement, 1011-1018
Blood urea nitrogen, *see* BUN in ESRD
BMI, *see* Body mass index
BMP-7 (bone morphogenetic protein-7) in renal development, 386, 389-390
Body composition of ESRD patients on HD, plasma leptin relationship to, 655-661
Body fat of ESRD patients on HD, plasma leptin relationship to, 655-661
Body mass index (BMI)
  of ESRD patients on HD, 656, 831 *see also* Body mass index of ESRD patients on chronic HD
  restricted dietary K effects on, 19-27
  weekly Cr clearance and Kt/V_{urea} on CAPD and, 496
Body mass index (BMI) of ESRD patients on chronic HD
  elevated serum P and serum Ca $\times$ PO_4 product and, 610-612
  heart rate variability and, 604
  IL-6 effects on, 95
  as predictor of mortality, 997-1006
Body weight (BW)
  at birth, of infants born to ESRD mothers on HD, 760, 769-772
  of CVVH and CVVHD patients, vancomycin clearance and, 1021
  of HD patients, *see* Body weight of ESRD patients on CAPD and/or HD
  of PKD patients, vitamin E effects and, 690
  and progression of chronic DN, 162
  of RCIN patients, 676
  restricted dietary K effects on, 22
Body weight (BW) of ESRD patients on CAPD and/or HD
  on chronic HD, 95, 604
  plasma leptin levels and, 656
  vascular access thrombosis and survival and, 251
  weekly Cr clearance and Kt/V_{urea} on CAPD and, 496
  see also Interdialytic weight gain
Bone marrow chimeras, mixed, thymic tolerance to transplantation and, 207
Bone marrow/solid organ transplantation, microchimerism with, 200-201
Bone morphogenetic protein-7 (*BMP-7*) in renal development, 386, 389-390
Bone remodeling, calcitriol role in, 737-738
BP, *see* Blood pressure
Brachial plexus, compression of, due to subclavian pseudoaneurysm from cannulation of jugular vein catheter, 694-697
Brachiocephalic vein catheter thrombosis, pseudotumor cerebri as complication of, 5:E3
Branched DNA (bDNA) signal amplification assay of HCV infection in chronic HD patients, 647-654
BUN (blood urea nitrogen) in ESRD
  effects of delayed referral to nephrologist on, 403
  see also BUN in ESRD patients on HD
BUN (blood urea nitrogen) in ESRD patients on HD
  chronic HD, 95, 604
  HD adequacy and, 135-141
  high-flux HD, prediction of equilibrated postdialysis, by ANN, 638-646
  IDWG and, 831, 832
  and PD, effects of gastroparesis treatment on, 64
  plasma leptin levels and, 656
BW, *see* Body weight

C, *see* Complement
C3 (complement 3)
in postinfectious GN with TMA, 515
in types I and III MPGN, 427-434
C3dg (complement 3dg) in idiopathic MN, 3, 7
C5b-9 (complement 5b9) in idiopathic MN, 3, 7
Ca (calcium)
calcitriol role in maintaining homeostasis of, 729-742
dietary, rickets and deficiency in, 369-374
hypotension on chronic HD and, 814
see also Ca in ESRD patients on CAPD and/or HD
Ca (calcium) carbonate, phosphate-binding capacity of Ca ketoglutarate and, on chronic HD, 257-262
Ca (calcium) channel blockers to retard chronic DN progression, 167
Ca (calcium) in ESRD patients on CAPD and/or HD
Ca x P_i in cerebrovascular events in HD patients, 994
effects of metabolic acidosis correction on, in chronic HD patients, 37
HTN control and, 621
in nondiabetic elderly patients on CAPD, 484
with RLS, 326
serum, *see* Serum Ca in ESRD patients on HD
Ca (calcium) ketoglutarate, phosphate-binding capacity of Ca carbonate and, on chronic HD, 257-262
Calcitriol [1,25-$(OH)_2D_3$; 1,25-dihydroxycholecalciferol D_3]
effects of, on osteoblasts and Ca homeostasis, 729-742
rickets and, 369, 370, 372, 373
Calcium, *see* Ca
Cancer in ESRD patients
on chronic HD, elevated serum P and serum Ca × PO_4 product, 610-612
screening for, 577-580
CAPD, *see* Continuous ambulatory peritoneal dialysis
Capitation, global, primary care and, 580-581
Capsular artery pseudoaneurysm, renal, percutaneous renal biopsy of, 533-535
Captopril, effects of, on dexamethasone-induced proteinuria, 448
Cardiac β_2-microglobulin (β_2-m) amyloidosis in long-term HD, 3:E4
Cardiac output, effects of stationary cycling on, during HD for ESRD, 631-637
Cardiopulmonary recirculation, access flow measurement and, 503, 505
Cardiovascular (CV) response to stationary cycling during HD, 631-637
Caregiver time required by chronic HD patients, 818-829, 5:E5
Catecholamines
Na balance and renal dopamine system, 2:xliii-xlv
restricted dietary K effects on excretion of, 22
Catheters, HD
PC as complication of brachiocephalic vein thrombosis associated with subclavian vein, 5:E3
permanent central venous, high-dose intradialytic urokinase to restore patency of, 841-847
see also Catheters, jugular vein HD
Catheters, jugular vein HD
brachial plexus compression due to subclavian pseudoaneurysm from cannulation of double-lumen catheters, 694-697
internal TwinCath, blood flow and recirculation rates in, 87-92
PC as complication of brachiocephalic vein thrombosis associated with, 5:E3
CCPD, *see* Continuous cycling peritoneal dialysis
CD11b (leukocyte Mac-1), HD for CRF and, 67-73
CD62L (L-selectin), HD for CRF and, 67-73
Cell differentiation, PMO, and cytokine production in NIPD and CCPD, 234-241
Cell proliferation, SF, in IDDM, integrin and type I collagen expression in, 293-300
Central nervous system vasculitis, ANCA-negative, with Goodpasture's syndrome, 345-349
Central venous catheters (CVCs), permanent HD, high-dose intradialytic urokinase to restore patency of, 841-847
Cerebral hemorrhage in chronic HD patients, incidence, outcome, and risk factors for, 991-996
Cerebrovascular disease in chronic HD patients, incidence, outcome, and risk factors for, 991-996
cGMP (cyclic guanosine monophosphate), hypotension on chronic HD and, 814
Chemokines, renal
correlative studies of, 1071-1074
in vitro studies of, 1069-1071
neutralization of, *see* Neutralization of chemokines
receptors of, 1076-1077
Chemotactic factors, renal inflammation and, 1065-1083
chemokines as, *see* Chemokines, renal
chemotactic factors relevant to kidneys, 1066
complement-derived, 1067-1069
osteopontin in interstitial inflammation, 1078-1079
CHF (congestive heart failure), fenoldopam effects on, 750-751
Children
contiguous gene syndrome in, 1038-1043
IgAN in, ACE gene polymorphism in, 774-779
long-term moderate dose CsA therapy of NS in, 932-939
Chimeras, mixed bone marrow, thymic tolerance to transplantation and, 207
Chlorambucil for crescentic IgAN with low-grade B-cell MALT lymphoma, 713-718
Chloride (Cl), serum, in ESRD patients on chronic HD, IL-6, malnutrition and, 95
Cholangitis, anuric ARF complicating primary sclerosing, OLT for, 360-363
Cholesterol
in ESRD patients on CAPD and/or HD, 265, 268, 484, 621, 993, 994
hypercholesterolemia in renal transplant recipients, probucol effects on, 356-359
lovastatin effects on, in PA nephrosis, 190-194
in NIDDM, and risk of DN, 668, 670
total, *see* Total cholesterol
Cholinesterase in ESRD patients on chronic HD, IL-6, malnutrition and, 95

Chronic glomerulonephritis (GN), as primary diagnosis, 4:xlvi
and cerebrovascular events in chronic HD patients, 992
in pregnant patients on HD, 757
renal transplant rejection and, S1:35
Chronic hematuria in IgAN, 965
Chronic hemodialysis (HD) for ESRD, 4:xlv-xlvii, 809-829, 986-996
acute hypotension during, enhanced NO production and, 809-817
heart rate variability and, *see* Variability, heart rate, on chronic HD
IL-6 and malnutrition on, 93-100
incidence, outcome, and risk factors for cerebral hemorrhage and cerebrovascular disease in patients on, 991-996
metabolic acidosis correction effects on albumin and, 35-40
PCS for patients on, 818-829, 5:E-5
phosphate-binding capacity of Ca ketoglutarate and Ca carbonate on, 257-262
serum P and serum Ca × PO_4 product associated with mortality risk on, 607-617
SRI for urea determined by partial spent dialysate collection method in patients on, 986-990
see also Hepatitis C virus infection in chronic HD patients
Chronic nephropathy
therapeutic strategies to retard progression of, 161-170
see also specific conditions
Chronic renal failure (CRF), 3:lix
fenoldopam effects in, 751
IGF-I in, 95, 911-913
see also End-stage renal disease
Chronicity index, mesangial IgG deposition and, as risk factors for HTN and renal failure in early IgAN, 962-970
Churg-Strauss syndrome, peripheral blood eosinophilia in, 1032-1037
Ciprofloxacin, ARF due to overdose of, apoptosis in, 710-712
Cirrhosis, fenoldopam effects on, 750-751
Cl (chloride), serum, in ESRD patients on chronic HD, IL-6, malnutrition and, 95
Classical nuclear receptor-mediated actions of calcitriol, 731-734
Classification
Banff, of acute kidney transplant rejection, S1:19-25, S1:31-39
of chronic HD patients, system of, 818-829, 5:E5
Clinical course
of postpartum NS, 724-725
see also Progression of renal disease *and specific conditions*
Clinical features and presentation
of contiguous gene syndrome, 1039
of FAP type I, 942
of transplant RAS, 142-144
see also specific conditions
Clinical trials
multicenter, of FK506 in liver transplantation, S1:8-11; *see also* FK506, clinical trials with
see also Clinical trials of acute kidney transplant rejection; Controlled clinical trials
Clinical trials of acute kidney transplant rejection
definitions of rejection and controlled, in medical literature, S1:3-6
with FK506, S1:11
see also Multicenter clinical trials of acute kidney transplant rejection
Clonal deletion, *see* Thymic transplant tolerance
Clotting, dialyzer, as barrier to HD adequacy, 593-601
CME, *see* Continuous medical education
Cold water immersion, ARF in accidental hypothermia of, 856-859
Collaborative care model, nephrology nurse practitioners in, 786-793
Collagen type I, expression of integrin and, in SFs with renal lesions in IDDM, 293-300
Collagen type IV genes, mutations of, in autosomal recessive AS, 6:E4
Colonic angiodysplasias in ESRD patients on HD, tranexamic acid for GI bleeding due to, 536-538
Combination transplantation, microchimerism and, 198-201
Compensatory renal growth, IGF-I and -II in, 908-911
Complement (C)
chemotactic factors derived from, in renal inflammation, 1067-1069
see also C3; C3dg; C5b-9; Hypocomplementemia
Compliance
with CCPD and CAPD, supply inventories during home visits measuring, 101-107
with chronic HD, elevated serum P and serum Ca × PO_4 product, 610-612
noncompliance as barrier to HD adequacy, 593-601
Conflicts with families over dialysis discontinuation, management of, 873-877
Congestive heart failure (CHF), fenoldopam effects on, 750-751
Contiguous gene syndrome, haplotype studies of, 1038-1044
Continuous ambulatory peritoneal dialysis (CAPD)
compliance with, supply inventories during home visits measuring, 101-107
effects of osmolality, sterilization process of CAPD fluids, and glucose concentration on PMN functions and cytokine production by PBMCs, 273-281
for ESRD, *see* Continuous ambulatory peritoneal dialysis for ESRD
Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
adequacy of, 101-107
in elderly nondiabetic patients, 479-490
reducing cost of, by switching from vendor-provided to program-provided system for general medical supplies, 662-665
weekly Cr clearance and Kt/V_{urea} on, 495-501
see also Metabolic acidosis in ESRD patients on CAPD and/or HD; Nutritional status of ESRD patients on CAPD and/or HD; Peritonitis and CAPD for ESRD; Pregnancy in ESRD patients on CAPD and/or HD
Continuous cycling peritoneal dialysis (CCPD)
adequacy and compliance with, supply inventories during home visits measuring, 101-107

for ESRD, *see* Continuous cycling peritoneal dialysis for ESRD
PMO differentiation and cytokine production in NIPD and, 234-241
Continuous cycling peritoneal dialysis (CCPD) for ESRD
reducing cost of, by switching from vendor-provided to program-provided system for general medical supplies, 662-665
weekly Cr clearance and Kt/V_{urea} on, 495-501
Continuous medical education (CME), 133-134
exercises on, 1: E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
Continuous quality improvement of HD for ESRD, HCFA report on, 584-592
Continuous renal replacement therapy (CRRT)
CVVH as, vancomycin clearance by, 1019-1027
see also Continuous ambulatory peritoneal dialysis; Continuous ambulatory peritoneal dialysis; Continuous venovenous hemodialysis
Continuous venovenous hemodialysis (CVVHD)
high-flux, for ARF with MOF, 227-233
vancomycin clearance by, 1019-1027
Continuous venovenous hemofiltration (CVVH), vancomycin clearance by, 1019-1027
Contraindications to urokinase, 844
Controlled clinical trials
acute kidney transplant rejection and, defined, S1:3-6
of dietary protein restriction effects on rate of renal function decline, 954-961
Conventional hemodialysis, *see* Hemodialysis
Coronary heart disease, as primary diagnosis, elevated serum P and serum Ca × PO_4 product in chronic HD patients and, 610
Correlative studies of renal chemokines, 1071-1074
Corticosteroids, *see* Steroids
Cost
of delayed referral to nephrologist, 403-405
drug expenditures following renal transplantation, 283-292
reducing CAPD and/or CCPD, by switching from vendor-provided to program-provided system for general medical supplies, 662-665
of subspecialist-delivered primary care, effectiveness and, 575-576
see also Cost-effectiveness
Cost-effectiveness
of ACEIs in prevention of ESRD in IDDM, 49-54
of dialysis for ARF, 545-549
of pancreas transplantation for IDDM with ESRD, 794-802
of timely RRT initiation for ESRD, 415
Coupling factor for bone remodeling and Ca homeostasis, calcitriol as, 737-738
Cr, *see* Creatinine
C-reactive protein (CRP) in ESRD patients on chronic HD, IL-6, malnutrition and, 95
Creatinine (Cr)
Ca ketoglutarate and Ca carbonate effects on, 260
in CVVH and CVVHD patients, vancomycin clearance and, 1021
in DN, 44-46, 303
in ESRD, effects of delayed referral to nephrologist on, 403; *see also* Creatinine in ESRD patients on CAPD and/or HD
in FAP type I, 941
in IDDM, 294
in NIDDM, 949
plasma, *see* Plasma creatinine
in renal allograft rejection, S1:15-18
in rickets, 373
serum, *see* Serum creatinine
Creatinine (Cr) in ESRD patients on CAPD and/or HD
on chronic HD, 604, 610-612, 814
HTN control and, 621
or PD, in sexually dysfunctional ESRD males, 315, 316
plasma leptin levels and, 656
with RLS, 326
TIBC, malnutrition and, 265, 268
weekly Kt/V_{urea} and, on CAPD, 495-501
Crescentic glomerulonephritis (GN)
severe, immune-complex deposits, 550-554
see also Myeloperoxidase antineutrophil cytoplasmic antibodies, crescentic GN with
Crescentic IgA nephropathy (IgAN) with low-grade B-cell MALT lymphoma, chlorambucil for, 713-718
c-ret gene in renal development, 386-388
CRF, *see* Chronic renal failure
CRP (C-reactive protein) in ESRD patients on chronic HD, IL-6, malnutrition and, 95
CRRT, *see* Continuous renal replacement therapy
Cryoglobulin, IgMk-IgG, immunodeposition in GN induced by, 435-442
Cryoglobulinemic membranoproliferative glomerulonephritis (MPGN), TMA with HCV infection and, 521-526
CsA, *see* Cyclosporin A
CV (cardiovascular) response to stationary cycling during HD for ESRD, 631-637
CVCs (central venous catheters), permanent HD, high-dose intradialytic urokinase to restore patency of, 841-847
CVVH (continuous venovenous hemofiltration), vancomycin clearance by, 1019-1027
CVVHD, *see* Continuous venovenous hemodialysis
CyA, *see* Cyclosporine
Cyclic guanosine monophosphate (cGMP), hypotension on chronic HD and, 814
Cycling, stationary, CV response to, during HD, 631-637
Cyclosporin A (CsA)
adverse reactions between fluvoxamine, nefazodone and, 320-323
drug use concomitant with, for 3 years following transplantation, 283-292
hypercholesterolemia due to, probucol effects on, 356-359
laryngeal TB and, 701-705
lipid peroxidation and, 149-154
long-term moderate dose, for NS in children, 932-939
Cyclosporine (CyA), S1:7
see also FK506, clinical trials with
Cytochrome p450, effects of nefazodone and fluvoxamine on, 320-323

Cytokines
PBMC production of, effects of osmolality, sterilization process of CAPD fluids, and glucose concentration on, 273-281
PMO differentiation and production of, in NIPD and CCPD, 234-241
see also Chemokines, renal *and specific cytokines*

DA, *see* Dopamine A-1 agonist(s) for ARF; Dopamine system
Database of Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation, S1:31-39
Daugirdas blood-based quantification of HD, 1011-1018
Decision-making capacity of ESRD patients from whom dialysis was withdrawn or withheld, 467
Delayed referral to nephrologist for ESRD, 401-408
Deletion
clonal, *see* Thymic transplant tolerance
insertion/deletion polymorphism of ACE gene, DN and, 301-307
PKD1 and *TSC2* gene, contiguous gene syndrome and, 1038-1043
De novo hepatitis C virus (HCV) infection in chronic HD patients, 649-650
De novo renal diseases following renal transplantation, 928-931
Dense deposit disease, 2:E1
Deoxyribonucleic acid (DNA), bDNA signal amplification assay of HCV infection in chronic HD patients, 647-654
Development, *see* Renal growth and development
Dexamethasone, proteinuria induced by, 443-452
Diabetes mellitus (DM)
POEMs syndrome, erythema elevatum diutinum, rheumatoid arthritis, and steroid-dependent, as extramedullary manifestations of plasma cell dyscrasia, 4:E3
see also Diabetes mellitus, as primary diagnosis; Diabetic nephropathy; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
Diabetes mellitus (DM), as primary diagnosis
BP control and, 620
and cerebrovascular events on chronic HD, 992
HCV infection and, 922
HD adequacy and, 595, 597
heart rate variability and, 604
hypotension and, 625
male sexual dysfunction and, 314
and mortality on HD, 610-612
in pregnant women, 768
renal transplantation and, 285, 929, S1:35
Diabetic nephropathy (DN), 41-54, 587
anti-GBM nephritis with, 127-130
compliance with CAPD and CCPD in, 103
and HIV infection, 375-377
hypertensive, *see* Hypertensive diabetic nephropathy
immunohistochemical localization of renal ACE in, 301-307
mesangiolysis and, 566-569
orthostatic hypotension effects on urine volume and Na excretion in, 41-48
and TB in HD patients, 850
urokinase to restore CVC patency in, 843
see also Diabetes mellitus, as primary diagnosis; Insulin-dependent diabetes mellitus, ESRD with
Diabetic retinopathy, albuminuria as predictor of, in Hispanics with NIDDM, 947-953
Diagnosis, *see* Acute kidney transplant rejection, diagnosis of *specific diagnostic techniques and conditions*
Dialysate
effluent, on-line urea monitoring of, and high-flux HDF for ESRD, 74-80
hypertonic, effects of, on solute clearance and fluid balance, 1050-1057
on-line urea measurement with Biostat 1000 dialysate-based method, 1011-1018
SRI for urea determined by partial spent dialysate collection method, 986-990
Dialysis
cost-effective, for ARF, 545-549
patient selection for, 12-18, 131-132
withholding and/or withdrawal of, 464-472
see also Dialysate; Dialysis discontinuation; Hemodialysis; Peritoneal dialysis
Dialysis discontinuation, 868-883
advance care planning and, 464-472, 871-872
case presentation of, 868-869
comments on, 877-880
ethical justifications for, 464-472, 870
frequency of, and medical reasons for, 870
legal bases for, 870-871
managing conflicts with families over, 873-877
patients' and health care professionals' attitudes on, 872-873
practice guidelines on patient initiation to and withdrawal from dialysis, 874-875
questions and answers on, 880-882
Dialyzer, clotting of, as barrier to HD adequacy, 593-601
Dialyzer blood flow (BF), dilution techniques in measurement of, 502-508
Dietary Ca (calcium), rickets and deficiency in, 369-374
Dietary K (potassium), effects of restricted, on BP and Na excretion, 19-27
Dietary protein
fenoldopam effects on response to, 751
HD patients' intake of, middle molecule clearance and, 491-494
soy, effects of, on PKD progression, 55-61
see also Dietary protein restriction
Dietary protein restriction
for CRF, indication for HD and, 185-189
effects of, on rate of decline of renal function, 954-961, 1048-1049
to retard non-DN progression, 162-164
1,25-Dihydroxycholecalciferol D_3, *see* Calcitriol
Dilution techniques in measurement of dialyzer blood flow in, 502-508
Discontinuation of dialysis, *see* Dialysis discontinuation; Withholding and/or withdrawal of dialysis
Distal renal tubular acidosis (dRTA), immune-related, permeability defect with HCO_3 leak and, 527-532
DM, *see* Diabetes mellitus

DN, *see* Diabetic nephropathy
DNA (deoxyribonucleic acid), bDNA signal amplification assay of HCV infection in chronic HD patients, 647-654
Dominant polycystic kidney disease, *see* Autosomal dominant polycystic kidney disease
Dopamine A-1 (DA-1) agonist(s) for ARF, 743-755
Dopamine (DA) system, renal, Na balance and, 2:xliii-xlv
Dose
  Ca carbonate and Ca ketoglutarate, 259
  ciprofloxacin overdose-induced ARF, 710-712
  HD, on-line urea monitoring effects and, 74-80
  high-dose intradialytic urokinase to restore patency of permanent HD CVCs, 841-847
  long-term moderate dose CsA therapy of NS in children, 932-939
  rHuEPO, IV iron dextran effects on, 837
Double-lumen catheters, jugular vein HD, brachial plexus compression due to subclavian pseudoaneurysm from cannulation of, 694-697
Down syndrome (trisomy 21), renal disease in, 329-335
dRTA (distal renal tubular acidosis), immune-related, permeability defect with HCO_3 leak and, 527-532
Drugs
  concomitant with CsA therapy for 3 years following transplantation, 283-292
  for severe bilateral atherosclerotic renovascular disease, incidence of ESRD with, 971-977
  see also Immunosuppression *and specific drugs*
Dyscrasia, extramedullary manifestations of plasma cell, rheumatoid arthritis, erythema elevatum diutinum, POEMS syndrome, and steroid-dependent DM as, 4:E3

Early IgA nephropathy (IgAN; Berger's disease), mesangial IgG deposition and chronicity index as risk factors for HTN and renal failure in, 962-970
Echocardiography of heart rate variability in ESRD patients on chronic HD, 602-606
ECM (extracellular matrix), expression of integrin and type I collagen in SFs with renal lesions in IDDM and, 293-300
Economics, *see* Cost
Education, *see* Continuous medical education; Education of ESRD patients
Education of ESRD patients
  compliance and, 103
  HD adequacy and, 595, 597
  of hypertensive patients, 30, 31
Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation
  database of, S1:31-39
  introduction to, S1:1-2
  questionnaire of, reviewed, S1:26-30
  see also Acute kidney transplant rejection
Effluent dialysate, on-line urea monitoring of, and high-flux HDF for ESRD, 74-80
α8β1 (alpha8beta1) in renal development, 386, 390-391
Elastase, ANCAs to PMN, enhancing elastase activity in systemic vasculitis, 978-985
Elderly patients, nondiabetic ESRD, on CAPD, 479-490
Electron microscopy (EM)
  of IgMk-IgG cryoglobulin-induced GN, 435-442
  of TMA with cryoglobulinemic MPGN and HCV infection, 523
  see also specific conditions
EM, *see* Electron microscopy
Emboli, catheter-related pulmonary, 845-846
Endocrine factors, effects of postural change on, in DN and non-DN, 43-45
Endogenous solute clearance
  at initiation of RRT, 412
  see also Kt/V on HD
Endothelial injury, mesangiolysis and, 563-569
  mild, recurrent mesangiolysis and, 566-569
Endothelin-1 (ET-1), hypotension on chronic HD and, 814
End-stage renal disease (ESRD)
  diabetic, *see* Diabetes mellitus, as primary diagnosis; Diabetic nephropathy
  incidence of, with medically treated severe bilateral atherosclerotic renovascular disease, 971-977
  nurse practitioners in care of patients with, 786-793
  rhabdomyolysis following surgery in patients with, 539-544
  see also Chronic renal failure; Hemodialysis for ESRD; Hypertensive end-stage renal disease; Peritoneal dialysis for ESRD; Primary care of ESRD patients, nephrologists as providers of; Progression to ESRD; Referral to nephrologist for ESRD; Renal transplantation
Eosinophilia
  renal eosinophilic infiltration and peripheral blood, MPO-ANCA-positive tubulointerstitial nephritis and necrotizing crescentic GN with, 1032-1037
  reversible renal failure with hypereosinophilia during IFN-α therapy, 121-126
Epidemiology
  of HCV and HBV infections in chronic HD patients, 649
  see also Incidence; Prevalence
EPO (erythropoietin), *see* Recombinant human erythropoietin for ESRD patients on CAPD and/or HD
Equilibrated postdialysis BUN (blood urea nitrogen), prediction of, by ANN, in high-flux HD, 638-646
Equilibration test, peritoneal, 495-501
Erythema elevatum diutinum, POEMS syndrome, rheumatoid arthritis, steroid-dependent DM and, as extramedullary manifestations of plasma cell dyscrasia, 4:E3
Erythropoietin, *see* Recombinant human erythropoietin for ESRD patients on CAPD and/or HD
ESIs (exit-site infections) in nondiabetic elderly ESRD patients on CAPD, 482-483
ESRD, *see* End-stage renal disease
Estradiol in sexually dysfunctional ESRD males on HD or PD, 315
ET-1 (endothelin-1), hypotension on chronic HD and, 814
Ethics of withholding and/or withdrawing dialysis, 464-472, 870
Ethnicity, *see* Race and ethnicity
European trials with FK506, S1:10
Euthyroid sick syndrome, and toxic multinodular goiter in ESRD patient on HD, 698-700

Exercise, CV response to stationary cycling, during HD, 631-637
Exit-site infections (ESIs) in nondiabetic elderly ESRD patients on CAPD, 482-483
Expenditures
  for drugs following renal transplantation, 283-292
  see also Cost
Extracellular matrix (ECM), expression of integrin and type I collagen in SFs with renal lesions in IDDM and, 293-300
Extramedullary manifestations of plasma cell dyscrasia, rheumatoid arthritis, erythema elevatum diutinum, POEMS syndrome, steroid-dependent DM and as, 4:E3

Facilities, Pakistani renal services, 4:xlv, 4:xlviii
Factor H in types I and III MPGN, 427-434
Familial amyloid polyneuropathy (FAP) type I (Portuguese type), distribution and characterization of amyloid deposits in, 940-946
Familial lobular glomerulopathy in NIDDM, 6:E3
FAP (familial amyloid polyneuropathy) type I, distribution and characterization of amyloid deposits in, 940-946
Fatigue, postdialysis, TNF-α role in, 1007-1010
Fe, *see* Iron in ESRD patients on CAPD and/or HD
Fenoldopam, renal effects of, 748-752
Ferritin in ESRD patients on CAPD and/or HD
  in elderly nondiabetic patients, 484
  with RLS, 326
  see also Ferritin in ESRD patients on HD and rHuEPO therapy
Ferritin in ESRD patients on HD and rHuEPO therapy
  iron dextran infusion and, 83, 837
  TIBC, transferrin and, 263-272, 3:E3
Fetal complications of pregnancy in ESRD women on HD, 770
Fever, thrombocytopenia, anasarca, and ARF, 890-895
Fibrillary glomerulonephritis (GN), 6:E3
Fibrillary/immunotactoid glomerulonephritis (GN) in siblings, 5:E4
Fibrin sleeve (sleeve thrombus) around CVCs, 845
Fibrinogen, dexamethasone effects on, 443-452
Fibroblasts, skin, with renal lesions in IDDM, expression of integrin and type I collagen in, 293-300
Fibronectin in familial lobular glomerulopathy, 6:E3
FK506 (tacrolimus)
  nephrotoxicity of, acute rejection due to, S1:15-18
  in OLT, 360-363
  see also FK506, clinical trials with
FK506 (tacrolimus), clinical trials with, S1:7-14
  in kidney and other organ transplants, S1:11
  multicenter trials in liver transplant, S1:8-11
  pilot treatment experience, S1:8
Fluid balance, high-fill volumes optimizing solute clearance and, 1050-1058
Fluid overload
  metabolic acidosis and, 886-888
  volume-induced HTN on HD and, 803-808
Fluvoxamine, adverse drug reactions between CsA and, 320-323
Focal segmental glomerulosclerosis (FSGS)
  HD vascular access thrombosis and survival in, race and, 250-256
  MMF for, 215
  recurrent, *see* Recurrent focal segmental glomerulosclerosis following renal transplantation
  renal transplant rejection and, S1:35
Follicle stimulating hormone (FSH) in sexually dysfunctional ESRD males on HD or PD, 315
Fragmin, effects of, on dexamethasone-induced proteinuria, 448
Frequency of dialysis discontinuation, 870
FSGS, *see* Focal segmental glomerulosclerosis
FSH (follicle stimulating hormone) in sexually dysfunctional ESRD males on HD or PD, 315
Functional status of ESRD patients, 587
Furosemide, effects of, on Na and K excretion in dRTA, 530

Gammopathy, monoclonal, in NIDDM, 1058-1064
Gastrointestinal (GI) bleeding due to colonic angiodysplasias in ESRD patients on HD, tranexamic acid for, 536-538
Gastroparesis, occult, effects of treatment of, on malnutrition of HD and PD patients, 62-66
GDNF in renal development, 386, 388
Gender, *see* Sex
Gene disruption, 392-394
  conclusion on, 393-394
  discussion on, 392-393
  limitations of, and future directions in, 393
  see also Molecular renal development
General medical supplies, reducing CAPD and/or CCPD cost by switching from vendor-provided to program-provided system for, 662-665
Genetics
  of idiopathic MN, 2-4
  see also Angiotensin II, gene expression and; Chimeras; Deletion; DNA; Gene disruption; Genotypes; Haplotype; Heterozygosity; Microchimerism; mRNA; Mutations; Polymorphism, ACE gene; Siblings *entries beginning with terms*: Autosomal, Familial, Molecular
Genistein, effects of, on PKD progression, 55-61
Genotypes, HCV, in renal transplant candidates, 923-924
Gestational age, *see* Age, gestational
Gestational hypertension (HTN), β_2-m in, 308-312
GFR, *see* Glomerular filtration rate
GI (gastrointestinal) bleeding due to colonic angiodysplasias in ESRD patients on HD, tranexamic acid for, 536-538
Giant cell vasculitis (temporal arteritis), renal failure in, 1044-1047
Global capitation, primary care and, 580-581
Glomerular changes in idiopathic MN, 4-5
Glomerular disease
  in Down syndrome, 329-335
  MMF for, 213-217
  see also specific conditions
Glomerular distribution of amyloid deposits in FAP type I, 942, 944

Glomerular filtration rate (GFR)
in bilateral atherosclerotic renovascular disease, 972, 974
DA-1 agonist effects on, 743, 745-752
dexamethasone and hyperfiltration, 443-452
dietary protein restriction effects on, 954-961
HTN control and ultrafiltration, 621
regulation of IGF-I-induced increase in, 905-906
Glomerular hemodynamics
IGF-I and, 904-907
see also Glomerular filtration rate
Glomerular macrophages, effects of lovastatin on MCP-1 mRNA expression and influx of, in PA nephrosis, 190-194
Glomerular paramesangial deposits associated with hypocomplementemia in MPGN types I and III, 427-434
Glomerulonephritis (GN), 3:lvii-lix
chemotactic factors in, *see* Chemotactic factors, renal inflammation and
MG with, 350-355
see also Glomerulonephritis, as primary diagnosis *and specific types of glomerulonephritis*
Glomerulonephritis (GN), as primary diagnosis
BP control and, 620
chronic, *see* Chronic glomerulonephritis, as primary diagnosis
in elderly nondiabetic patients, 481
HD adequacy and, 595, 597
HH and, 625
male sexual dysfunction and, 314
renal transplantation and, 285, 510, 929
Glomerulosclerosis (GS)
dexamethasone-induced, 443-452
diabetic, HIV infection and, 375-377
glomerular macrophage influx and MCP-1 mRNA expression role in, 190-194
see also Focal segmental glomerulosclerosis
Glucose
in DN, 44-46
effects of osmolality, sterilization process of CAPD fluids, and concentration of, on PMN functions and cytokine production by PBMCs, 273-281
in ESRD patients on CAPD and/or HD, 484, 656
serum, dexamethasone effects on, 445
Glutathione (GSH), renal, vitamin E effects on, 687-693
Glycemic control to retard DN progression, 167-168
Glycosylated Hb (hemoglobin) in NIDDM, 949, 950
GMP (guanosine monophosphate), cyclic, hypotension on chronic HD and, 814
GN, *see* Glomerulonephritis
Goiter, toxic nodular, in ESRD patient on HD, radioactive iodine ablation of, 698-700
Goodpasture's syndrome, ANCA-negative central nervous system vasculitis with, 345-349
Gradient defect, with HCO_3 leak and immune-related dRTA, 527-532
Graft survival, HD vascular access, race and, 250-256
Granulocytes, effects of HD and PD for CRF on function of, 70-71
Granulomatosis, *see* Wegener's granulomatosis, ANCAs in
Growth, *see* Renal growth and development
GS, *see* Glomerulosclerosis
GSH (glutathione), renal, vitamin E effects on, 687-693
Guanosine monophosphate (GMP), cyclic, hypotension on chronic HD and, 814
Guidelines
of JNC sixth report on antihypertensive therapy, 864-867
practice, on patient initiation to and withdrawal from dialysis, 874-875

Habu venom nephropathy, mesangiolysis due to, 560-562
Hanta virus in NE, 116-120
Haplotype studies of contiguous gene syndrome, 1038-1044
Hb (hemoglobin)
in ESRD, effects of delayed referral to nephrologist on, 403; *see also* Hb in ESRD patients on CAPD and/or HD
glycosylated, in NIDDM, 949, 950
in postinfectious GN with TMA, 515
Hb (hemoglobin) in ESRD patients on CAPD and/or HD
in elderly nondiabetic patients, 484
IV iron dextran effects on, 835-840
and on PD, in sexually dysfunctional males, 315, 316
with RLS, 326
TIBC, malnutrition and, 265, 268
HbA_{1c} (hemoglobin A_{1c})
in DN, 42, 670
in IDDM, 294
HBV (hepatitis B virus) infection in chronic HD patients, epidemiology of, 649
HCFA (Health Care Financing Administration), report of, on dialysis adequacy, 584-592
HCO_3 (bicarbonate)
Ca ketoglutarate and Ca carbonate effects on, 260
in metabolic acidosis, 867-868
permeability defect with HCO_3 leak and immune-related dRTA, 527-532
serum, *see* Serum HCO_3 in ESRD
Hct, *see* Hematocrit
HCV, *see* Hepatitis C virus infection
HD, *see* Hemodialysis
HDF (hemodiafiltration), high-flux, for ESRD, 74-80, 618-623
HDM (hemodynamic monitor), HD access recirculation measured with, 242-249
Health Care Financing Administration (HCFA), report of, on dialysis adequacy, 584-592
Health care professionals
attitudes of, toward dialysis discontinuation, 872-873
nurse practitioners in collaborative care model, 786-793
Health care system structure, delayed referral to nephrologists and, 402
Heart failure, congestive, fenoldopam effects on, 750-751
Heart rate
DA receptor stimulation effects on, 745
restricted dietary K effects on, 19-27
see also Heart rate of ESRD patients on HD
Heart rate of ESRD patients on HD
on chronic HD, *see* Variability, heart rate, on chronic HD
stationary cycling effects on, 631-637
Hematocrit (Hct)
in CVVH and CVVHD patients, vancomycin clearance and, 1021

in DN, 44-46
in ESRD, 403, 515; *see also* Hematocrit in ESRD patients on HD
in gestational HTN, 310
Hematocrit (Hct) in ESRD patients on HD
on chronic HD, 95, 604, 610
HH and, 626
PD, and CAPD, effects of gastroparesis therapy on, 64
and on rHuEPO therapy, 83, 621
stationary cycling effects on, 631-637
vascular access thrombosis and survival and, in AIDS patients, 251
Hematuria
chronic, in IgAN, 965
dexamethasone-induced, 445
Hemodiafiltration, high-flux, for ESRD, 74-80, 618-623
Hemodialysis (HD)
for ESRD, *see* Hemodialysis for ESRD
long-term, cardiac β_2-m amyloidosis and, 3:E4
TB and anergy on, 848-852
see also Continuous venovenous hemodialysis
Hemodialysis (HD) for ESRD
CV response to stationary cycling during, 631-637
dietary protein restriction and indication for, 185-189
effects of, on soluble L-selectin and leukocyte Mac-1, 67-73
HCFA report on improvement of, 584-592
HCV infection and, 920-927; *see also* Hepatitis C virus infection in chronic HD patients
plasma leptin relationship to body composition in patients, 655-661
and radioactive iodine ablation of TMNG, 698-700
with RLS, biochemical findings on, 324-328
testosterone replacement and vacuum tumescence therapy for impotence in, 313-319
volume-induced HTN on, NPY and, 803-808
see also Adequacy of HD for ESRD; Blood pressure on HD for ESRD; Chronic hemodialysis for ESRD; Hemorrhages in ESRD patients on HD; High-flux hemodialysis for ESRD; Interdialytic weight gain; Metabolic acidosis in ESRD patients on CAPD and/or HD; Nutritional status of ESRD patients on CAPD and/or HD; Pregnancy in ESRD patients on CAPD and/or HD; Recombinant human erythropoietin for ESRD patients on CAPD and/or HD; Vascular access, HD
Hemodialysis hypotension (HH) in ESRD, sertraline hydrochloride for, 624-630
Hemodynamic monitor (HDM), HD access recirculation measured with, 242-249
Hemodynamics, *see* Blood flow; Blood pressure; Heart rate; Renal hemodynamics
Hemofiltration, continuous venovenous, vancomycin clearance by, 1019-1027
Hemoglobin, *see entries beginning with acronym*: Hb
Hemolytic anemia, rifampicin-associated, 108-115
Hemolytic uremic syndrome (HUS)
ARF with thrombocytopenia and, 890-895
postinfectious GN, TMA and, 513-520
Hemorrhages
spontaneous splenic, with Wegener's granulomatosis, 860-862
see also Hemorrhages in ESRD patients on HD
Hemorrhages in ESRD patients on HD
chronic HD, incidence, outcome, and risk factors for cerebral hemorrhages, 991-996
GI, due to colonic angiodysplasias in, tranexamic acid for, 536-538
Heparin
and cerebrovascular events in chronic HD patients, 993, 994
effects of, on dexamethasone-induced proteinuria, 443-452
with high-dose intradialytic urokinase to restore patency of permanent HD CVCs, 841-847
Hepatitis B virus (HBV) infection in chronic HD patients, epidemiology of, 649
Hepatitis C virus (HCV) infection
in HD patients, 920-927; *see also* Hepatitis C virus infection in chronic HD patients
in renal transplant candidates, 920-927
TMA with cryoglobulinemic MPGN and, 521-526
Hepatitis C virus (HCV) infection in chronic HD patients
bDNA signal amplification assay of, 647-654
prevalence of HGV and, 218-226, 366-368
Hepatitis G virus (HGV) infection, prevalence of HCV and, in chronic HD patients, 218-226, 366-368
Hepatorenal syndrome, OLT for, 360-363
Heterozygosity, loss of, in contiguous gene syndrome, 1038-1043
HGV (hepatitis G virus) infection, HCV and, in chronic HD patients, compared, 218-226, 366-368
HH (hemodialysis hypotension) in ESRD, sertraline hydrochloride for, 624-630
High-density lipoprotein cholesterol, cerebrovascular events in chronic HD patients and, 993, 994
High-density lipoprotein in elderly nondiabetic ESRD patients on CAPD, 484
High-dose intradialytic urokinase to restore patency of permanent HD CVCs, 841-847
High-efficiency hemodialysis, *see* High-flux hemodialysis for ESRD
High-fill volumes optimizing solute clearance and fluid balance, 1050-1058
High-flux hemodiafiltration (HDF) for ESRD, 74-80, 618-623
High-flux hemodialysis (HD) for ESRD
BP control on conventional and, compared, 618-623
effects of low- and, on nutritional status, 491-494
prediction of equilibrated postdialysis BUN by ANN in, 638-646
Hispanics, *see* Race and ethnicity
Histology, *see* Renal biopsy; Renal histology
HIV (human immunodeficiency virus) infection
diabetic NS with, 375-377
see also HIVAN
HIVAN (HIV-associated nephropathy)
ACE inhibitors for, 719-722
chronic HD patients with, elevated serum P and serum Ca $\times$ PO_4 product in, 610-612

HD vascular access thrombosis and survival in, race and, 250-256
HLA
and acute kidney transplant rejection, S1:51-53, S1:55, S1:57
and idiopathic MN, 2-4
HLA-ABDR matches in renal transplantation of mentally retarded recipients, 511
Home visits, supply inventories during, measuring compliance with CCPD and CAPD, 101-107
Hospitalization for ESRD
effects of delayed referral to nephrologist on, 403-405
of nondiabetic elderly patients, 485
HTN, *see* Hypertension
Human erythropoietin, *see* Recombinant human erythropoietin for ESRD patients on CAPD and/or HD
Human immunodeficiency virus, *see* HIV infection
HUS, *see* Hemolytic uremic syndrome
25-Hydroxyvitamin D (25-OHD), rickets and, 369, 370, 372, 373
Hyperaldosteronism, primary, posttransplantation HTN due to, adrenal vein sampling in, 853-855
Hypercholesterolemia in renal transplant recipients, probucol effects on, 356-359
Hypereosinophilia, reversible renal failure with, during IFN-α therapy, 121-126
Hyperfiltration, dexamethasone and, 443-452
Hyperphosphatemia, Ca deficiency and, 374
Hypertension (HTN)
in DN, *see* Hypertensive diabetic nephropathy
fenoldopam effects on, 749-750
gestational, β_2-m in, 308-312
in idiopathic MN, 2, 3, 8
mesangial IgG deposition and chronicity index as risk factors for renal failure and, in early IgAN, 962-970
in MLN, 682
in NIDDM, 949, 950
post-renal transplantation, due to primary hyperaldosteronism, adrenal vein sampling in, 853-855
renovascular, Takayasu's arteritis and, 3:lix
as risk factor for cerebral hemorrhage and cerebrovascular disease in ESRD patients on chronic HD, 991-996
see also Antihypertensive therapy; Hypertensive end-stage renal disease; Hypertensive nephrosclerosis
Hypertensive diabetic nephropathy (DN), 42
apolipoprotein E4 polymorphism and, and risk of DN in NIDDM, 666-673
Hypertensive end-stage renal disease (ESRD), 4:xlvi
BP control in, *see* Hypertensive end-stage renal disease, BP control in
HH and, 625
male sexual dysfunction and, 314
in pregnant women on HD, 769
renal transplantation and, 285
risk factors for, 28-34
volume-induced, on HD, NPY and, 803-808
Hypertensive end-stage renal disease, BP control in, 618-623
ACEIs for, 177-184
Hypertensive nephrosclerosis
HD vascular access thrombosis and survival in, 250-256
as primary diagnosis, 481, 768, 992
Hyperthyroidism, and toxic multinodular goiter in ESRD patient on HD, 698-700
Hypertonic dialysate, effects of, on solute clearance and fluid balance, 1050-1057
Hypocomplementemia in MPGN types I and III, glomerular paramesangial deposits associated with, 427-434
Hypokalemia, posttransplantation HTN due to primary hyperaldosteronism and, adrenal vein sampling in, 853-855
Hyponatremia, "beer potomania" in non-beer drinkers and, 1028-1031
Hypophosphatemia in ESRD patients on chronic HD, 607-617
Hypotension
acute, during chronic HD, enhanced NO production and, 809-817
as barrier to HD adequacy, 595, 597
HD, sertraline hydrochloride for, 624-630
orthostatic, effects of, on urine volume and Na excretion in DN, 41-48
Hypothermia, accidental cold water immersion, ARF in, 856-859

I antigen in rifampicin-associated ARF, 108-115
I/D (insertion/deletion) polymorphism, ACE gene, DN and, 301-307
IDDM, *see* Insulin-dependent diabetes mellitus
Idiopathic membranous nephropathy (MN), prognostic factors in, 1-11
IDWG, *see* Interdialytic weight gain
IFN-α (interferon alpha), reversible renal failure with hypereosinophilia and, 121-126
Ig (immunoglobulin) deposition disease, monoclonal, mesangiolysis and, 569
IgA (immunoglobulin A) nephropathy (IgAN; Berger's disease), 4:E1
childhood, ACE gene polymorphism in, 774-779
crescentic, with low-grade B-cell MALT lymphoma, chlorambucil for, 713-718
diabetic, HIV infection and, 375-377
early, mesangial IgG deposition and chronicity index as risk factors for HTN and renal failure in, 962-970
IgA ANCAs in, 341-344
as primary diagnosis, renal transplantation and, 510, 929
IgAN, *see* IgA nephropathy
IGF, *see* Insulin-like growth factor system
IgG (immunoglobulin G)
chronicity index and mesangial deposition of, as risk factors for HTN and renal failure in early IgAN, 962-970
excretion of, in idiopathic MN, 2, 3, 6
IgMk-IgG (immunoglobulin Mk-immunoglobulin G) cryoglobulin-induced glomerulonephritis (GN), immune-complex deposits in, 435-442
IL-6 (interleukin-6), and malnutrition in ESRD patients on chronic HD, 93-100
Immune complex deposition
in IgMk-IgG cryoglobulin-induced GN, 435-442
severe crescentic GN with, 550-554

Immune-related distal renal tubular acidosis (dRTA), permeability defect with HCO_3 leak and, 527-532
Immunofluorescent microscopy
of TMA in cryoglobulinemic MPGN and HCV infection, 523
see also specific conditions
Immunoglobulin, *see entries beginning with acronym:* Ig
Immunohistochemistry
of autosomal recessive AS, 6:E4
renal ACE localization in DN with, 301-307
Immunosuppression
in mentally retarded renal transplant recipients, 511
of MLN, 681-686
see also Immunosuppression in acute kidney transplant rejection *and specific immunosuppressive drugs*
Immunosuppression in acute kidney transplant rejection
in Efficacy Endpoints database, S1:35, S1:37
response to, S1:51-53, S1:55, S1:57
Immunotactoid/fibrillary glomerulonephritis (GN) in siblings, 5:E4
Impotence in ESRD patients on PD or HD, testosterone replacement and vacuum tumescence therapy for, 313-319
IMT (inflammatory myofibroblastic tumor), steroid-responsive, renal failure due to infiltration by, 6:E5
Incidence
of cancer with ESRD, 578
of cerebral hemorrhage and cerebrovascular disease in chronic HD patients, 991-996
of ESRD with medically treated severe bilateral atherosclerotic renovascular disease, 971-977
of HCV infection in chronic HD patients, 647-654
of RCIN, 677
see also Prevalence
Indications
for CAPD of nondiabetic elderly ESRD patients, 479-490
for dialysis initiation and, 408
see also specific therapeutic modalities
Infections, *see specific infections*
Inflammatory myofibroblastic tumor (IMT), steroid-responsive, renal failure due to infiltration by, 6:E5
Initiation
to dialysis, practice guidelines on, 874-875
timely RRT, protecting against malnutrition, 410-412
Injury, *see* Renal injury and lesions
Inorganic phosphate, *see* Phosphate
Insertion/deletion (I/D) polymorphism, ACE gene, DN and, 301-307
Insulin, level of, in ESRD patients on HD, plasma leptin levels and, 656, 659, 660
Insulin-dependent diabetes mellitus (IDDM)
cell proliferation and expression of integrin and type I collagen in skin fibroblasts with renal lesions in, 293-400
see also Insulin-dependent diabetes mellitus, ESRD with
Insulin-dependent diabetes mellitus (IDDM), ESRD with
ACEIs to prevent ESRD in IDDM, cost-effectiveness of, 49-54
cost-effectiveness of pancreas transplantation for, 794-802
see also Diabetic nephropathy
Insulin-like growth factor-I (IGF-I), 901-915
in ARF, 913-915
in compensatory renal growth, 908-911
in CRF, 95, 911-913
effects of, on tubular function, 907-908
glomerular hemodynamics and, 904-907
in NS, 915
properties of, 901-902
receptors of, 902-903
regulation of, 903-904
Insulin-like growth factor-II (IGF-II), 907-911
in compensatory renal growth, 908-911
effects of, on tubular function, 907-908
properties of, 901-902
receptors of, 902-903
Insulin-like growth factor-binding proteins (IGF-BPs), 911-915
in ARF, 913-914
in CRF, 911-913
in NS, 915
properties of, 903
Insulin-like growth factor (IGF) system
in ARF, 913-915
in CRF, 911-913
expression of, in kidney, 903
in NS, 915
see also Insulin-like growth factor-I; Insulin-like growth factor-II; Insulin-like growth factor-binding proteins
Intact parathyroid hormone ($_i$PTH)
in ESRD patients on HD, 37, 324-328
with rickets, 373
Integrin, expression of type I collagen and, in SFs with renal lesions in IDDM, 293-300
Interdialytic weight gain (IDWG)
as index of good nutrition, 830-834
time on HD and, 618-623
Interferon alpha (IFN-α), reversible renal failure with hypereosinophilia and, 121-126
Interleukin-6 (IL-6), and malnutrition in ESRD patients on chronic HD, 93-100
Intermediate-time nuclear receptor-mediated actions of calcitriol, 736-737
Intermittent peritoneal dialysis (PD), nightly, PMO differentiation and cytokine production in CCPD and, 234-241
Internal jugular vein TwinCath, blood flow and recirculation rates in, 87-92
Interstitial glomerular distribution of amyloid deposits in FAP type I, 942-944
Interstitial inflammation, osteopontin in, 1078-1079
Interstitial nephritis
acute, with rifampicin-associated ARF, 113
chemotactic factors in, *see* Chemotactic factors, renal inflammation and
as primary diagnosis, 285, 314, 481, 757
see also Tubulointerstitial nephritis
Intradialytic urokinase, high-dose, to restore patency of permanent HD CVCs, 841-847
Intrarenal T cells, oligoclonal expansion of, in SLE, 418-426
Intravenous (IV) fenoldopam, effects of, 749, 750

Intravenous (IV) iron dextran for Fe-deficient ESRD patients on HD, effects of, on Fe stores, Hb, and rHuEPO requirements, 835-840
In vitro studies of renal chemokines, 1069-1071
Iodine, radioactive, ablation of TMNG with, in ESRD, 698-700
Iron (Fe) dextran for Fe-deficient ESRD patients on HD, rHuEPO therapy and, 81-86
  effects of IV iron dextran on Fe stores, Hb, and rHuEPO requirements, 835-840
Iron (Fe) in ESRD patients on CAPD and/or HD
  in elderly nondiabetic patients, 484
  with RLS, 326
  see also Iron in ESRD patients on HD and rHuEPO therapy
Iron (Fe) in ESRD patients on HD and rHuEPO therapy
  TIBC, transferrin and, 263-272, 3:E3
  see also Iron dextran for Fe-deficient ESRD patients on HD, rHuEPO therapy and
Ischemic acute renal failure (ARF), fenoldopam effects in, 752
IV, *see entries beginning with term*: Intravenous

Joint National Committee (JNC), sixth report of, on antihypertensive therapy, 864-867
Jugular vein, *see* Catheters, jugular vein HD

K (potassium)
  in chronic HD patients, 37, 95, 814
  furosemide effects on urinary excretion on, in dRTA, 530
  posttransplantation HTN due to primary hyperaldosteronism and hypokalemia, 853-855
  restricted dietary, effects of, on BP and Na excretion, 19-27
Kaposi's sarcoma (KS), lymphoma and, in renal transplant recipients, 706-709
Kimura's disease, recurrent FSGS associated with, following renal transplantation, 3:E3
KS (Kaposi's sarcoma), lymphoma and, in renal transplant recipients, 706-709
Kt/V on HD, 135-141, 492
  BP control and, 621
  on chronic HD, 37, 610-612, 994
  with high-flux HDF, 74-80
  see also Adequacy of HD for ESRD; Kt/V_{urea}; On-line urea measurement
Kt/V_{urea}
  on chronic HD, IL-6, malnutrition and, 95
  weekly Cr clearance and, on CAPD, 495-501

Laboratory data, *see* Biochemical findings
Laryngeal tuberculosis (TB), renal transplantation and, 701-705
Lawsuits, fear of, and patient selection for dialysis, 12-18
Lean mass of ESRD patients on HD, plasma leptin relationship to, 655-661
Legal bases for dialysis discontinuation, 870
Leptin, relationship of plasma, to body composition of ESRD patients on HD, 655-661
Leukocyte Mac-1 (CD11b), HD for CRF and, 67-73
LH (luteinizing hormone) in sexually dysfunctional ESRD males on HD or PD, 315
Light microscopy
  of TMA with cryoglobulinemic MPGN and HCV infection, 522-523
  see also specific conditions
Lim1 gene in renal development, 391
Linkage analysis of type IV collagen genes in autosomal recessive AS, 6:E4
Lipids
  CsA and peroxidation of, 149-154
  see also specific lipids
Lipoproteins
  high-density, in elderly nondiabetic ESRD patients on CAPD, 484
  serum, in renal transplant recipients, probucol effects on, 356-359
Liver/kidney transplantation, microchimerism with, 199-200
Liver transplantation
  multicenter trials with FK506 in, S1:8-11
  orthotopic, for PSC complicated by anuric ARF, 360-363
Lobular glomerulopathy, familial, in NIDDM, 6:E3
Log likelihood analysis, 825, 827, 5:E5
LOH (loss of heterozygosity) in contignuous gene syndrome, 1038-1043
Long-term hemodialysis (HD), cardiac β_2-m amyloidosis and, 3:E4
Long-term moderate dose CsA therapy of NS in children, 932-939
Long-term organ transplant tolerance, 197-212
  to combined transplantation, microchimerism and, 198-201
  in nature, 198
  thymus and, *see* Thymic transplant tolerance
Loss of heterozygosity (LOH) in contignuous gene syndrome, 1038-1043
Lovastatin, effects of, on glomerular macrophage influx and MCP-1 mRNA expression in PA nephrosis, 190-194
Low-density lipoprotein cholesterol in NIDDM, and risk of DN, 670
Low-dose urokinase to restore nonpositional malfunction of CVCs, 843
Low-flux hemodialysis (HD), effects of high- and, on nutritional status, 491-494
Low-grade B-cell MALT (mucosa-associated lymphoid tissue type) lymphoma, crescentic IgAN with, chlorambucil for, 713-718
Low-protein diet, *see* Dietary protein restriction
Lupus nephritis
  membranous, immunosuppressive therapy of, 681-686
  MMF for, 215
  NS and, in adolescents, 155-160
  oligoclonal expansion of intrarenal T cells in, 418-426
  pathology of, 5:l-lii
  proliferative forms of, 6:E1
  as primary diagnosis in pregnant ESRD women, 768
  see also Systemic lupus erythematosus
Luteinizing hormone (LH) in sexually dysfunctional ESRD males on HD or PD, 315

Lymphoma
KS and, in renal transplant recipients, 706-709
low-grade B-cell MALT, crescentic IgAN with, chlorambucil for, 713-718

β_2-m, *see* β_2-Microglobulin; β_2-Microglobulin amyloidosis
Macrophages, *see* Monocytes/macrophages
Magnesium, *see* Mg
Magnetic resonance imaging (MRI) of spontaneous splenic hemorrhage with Wegener's granulomatosis, 860-862
Maintenance hemodialysis, *see* Chronic hemodialysis for ESRD
Malignancy
MOF and, in ARF, cost-effectiveness of dialysis and, 546-547, 549
see also Cancer in ESRD patients
Malnutrition in ESRD patients on CAPD, HD, and/or PD
chronic HD, IL-6 and, 93-100
effects of occult gastroparesis treatment on, 62-66
low-protein diet and, 185-188
in nondiabetic elderly patients, 484-485
and plasma leptin relationship to body composition, 655-661
TIBC, transferrin and, 263-272, 3:E3
timely initiation of RRT protecting against, 410-412
MALT (mucosa-associated lymphoid tissue type) lymphoma, low-grade B-cell, crescentic IgAN with, chlorambucil for, 713-718
MAP (mean arterial pressure), *see* Blood pressure
Marital status of ESRD patients from whom dialysis has been withdrawn or withheld, 467
MCP-1 mRNA (monocyte chemoattractant protein-1 messenger ribonucleic acid), lovastatin effects on glomerular macrophage influx and expression of, in PA nephrosis, 190-194
MDS (myelodysplastic syndrome) with trisomy 7, MPO-ANCAs with, crescentic GN and, 336-340
Mean arterial pressure, *see* Blood pressure
Medical education, *see* Continuous medical education
Medical reasons for dialysis discontinuation, 870
Medical supplies, general, reducing CAPD and/or CCPD cost by switching from vendor-provided to program-provided system for, 662-665
Medical treatment, *see* Drugs
Membrane-initiated actions of calcitriol, 734-737
Membranoproliferative (mesangiocapillary) glomerulonephritis (MPGN), 1:E1, 2:E1, 3:E1
cryoglobulinemic, TMA with HCV infection and, 521-526
mesangiolysis and, 569
types I and III, glomerular paramesangial deposits associated with, 427-434
Membranous lupus nephritis (MLN), immunosuppressive therapy of, 681-686
Membranous nephropathy (MN)
idiopathic, prognostic factors in, 1-11
MMF for, 213-215
as primary diagnosis, 929
Mentally retarded renal transplantation recipients, 509-512
Mesangial IgG (immunoglobulin G) deposition, chronicity index and, as risk factors for HTN and renal failure in early IgAN, 962-970
Mesangial injury, mesangiolysis due to
mild, recurrent mesangiolysis and, 566-569
primary, 560-563
Mesangiocapillary glomerulonephritis, *see* Membranoproliferative glomerulonephritis
Mesangiolysis, 559-573
Mesangiopathic glomerulonephritis (GN), NS and, in adolescents, 155-160
Messenger ribonucleic acid, *see* mRNA
Metabolic abnormalities due to delayed referral to nephrologist, 403
Metabolic acidosis in ESRD patients on CAPD and/or HD
effects of correction of, on albumin in chronic HD patients, 35-40
nutritional status and, 884-889
MG (myasthenia gravis), GN with, 350-355
Mg (magnesium)
in nondiabetic elderly ESRD patients on CAPD, 484
in rickets, 373
Microalbuminuria
in DN, 49-54
in FAP type I, 941
in NIDDM, and risk of DN, 668, 670
Microangiopathy, *see* Thrombotic microangiopathy
Microchimerism, combined transplantation and, 198-201
β_2 (beta$_2$)-Microglobulin (β_2-m)
in ESRD patients on chronic HD, IL-6, malnutrition and, 95
excretion of, in idiopathic MN, 2, 3, 6-7
in gestational HTN, 308-312
β_2 (beta$_2$)-Microglobulin (β_2-m) amyloidosis in long-term HD, 3:E4
Microsatellites at 3'end of *PKD1* in contiguous gene syndrome, 1038-1043
Middle molecule, clearance of, and protein intake by HD patients, 491-494
Mild endothelial injury, recurrent mesangiolysis and, 566-569
Minimal change disease, MMF for, 215
Mixed bone marrow chimeras, thymic tolerance to transplantation and, 207
MLN (membranous lupus nephritis), immunosuppressive therapy of, 681-686
MMF, *see* Mycophenolate mofetil
MN, *see* Membranous nephropathy
Modality selection, RRT
and initiation of RRT, 414
and referral nephrologist, 405-406
see also Hemodialysis; Peritoneal dialysis; Renal transplantation
MOF, *see* Multiorgan failure, ARF with
Molecular analysis
of autosomal recessive AS, 6:E4
of contiguous gene syndrome, 1039
Molecular renal development, 383-397
gene disruption and, *see* Gene disruption
genes crucial in, 385-392
identification of genes involved in, 384-385

Monoclonal gammopathy in NIDDM, 1058-1064
Monoclonal Ig (immunoglobulin) deposition disease, mesangiolysis and, 569
Monocyte chemoattractant (MCP-1) mRNA (messenger ribonucleic acid), lovastatin effects on glomerular macrophage influx and expression of, in PA nephrosis, 190-194
Monocytes/macrophages
  glomerular, effects of lovastatin on MCP-1 mRNA expression and influx of, in PA nephrosis, 190-194
  peritoneal, cytokine production and differentiation of, in NIPD and CCPD, 234-241
  see also Chemotactic factors, renal inflammation and
Mononuclear cells, *see* Monocytes/macrophages; Peripheral blood mononuclear cells
Morbidity
  with ESRD, timely RRT initiation and, 412
  with metabolic acidosis in ESRD, 885, 888-889
  see also specific conditions
Mortality
  of ARF patients with MOF and malignancy, 546-547, 549
  of ESRD patients, referral to nephrologist and, 407-408; *see also* Mortality of ESRD patients on chronic HD
  on RRT, risk groups for, 475-476
  see also specific conditions
Mortality of ESRD patients on chronic HD
  nutritional indicators as predictors of, 997-1006
  serum P and serum Ca × PO_4 product associated with risk of, 607-617
MPGN, *see* Membranoproliferative glomerulonephritis
MPO-ANCAs, *see* Myeloperoxidase antineutrophil cytoplasmic antibodies, crescentic GN with
MRI (magnetic resonance imaging) of spontaneous splenic hemorrhage with Wegener's granulomatosis, 860-862
mRNA (messenger ribonucleic acid)
  MCP-1, lovastatin effects on glomerular macrophage influx and expression of, in PA nephrosis, 190-194
  TGF-β1, in ATS GN, 457
  see also Angiotensin II, gene expression and
Mucosa-associated lymphoid tissue type (MALT) lymphoma, low-grade B-cell, crescentic IgAN with, chlorambucil for, 713-718
Multicenter clinical trials
  of FK506 in liver transplant, S1:8-11
  see also Multicenter clinical trials of acute kidney transplant rejection
Multicenter clinical trials of acute kidney transplant rejection
  proposed consensus on definitions and endpoints for, S1:40-46
  role of renal biopsy in, S1:19-25
Multinodular goiter, toxic, in ESRD patient on HD, radioactive iodine ablation of, 698-700
Multiorgan failure (MOF), ARF with
  CVVHD for, 227-233
  and with malignancy, cost-effectiveness of dialysis for, 546-547, 549
Mutations, type IV collagen gene, in autosomal recessive AS, 6:E4
Myasthenia gravis (MG), GN with, 350-355
Mycophenolate mofetil (MMF) 364-365
  for glomerular disease, 213-217
Mycotic aneurysm, "true" renal artery graft, 1:E3
Myelodysplastic syndrome (MDS) with trisomy 7, MPO-ANCAs with, crescentic GN and, 336-340
Myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCAs), crescentic GN with
  in MDS with trisomy 7, 336-340
  MPO-ANCA-positive crescentic necrotizing GN and tubulointerstitial nephritis with renal eosinophilic infiltration and peripheral blood eosinophilia, 1032-1037
Myofibroblastic tumor, steroid-responsive inflammatory, renal failure due to infiltration by, 6:E5

Na (sodium)
  effects of metabolic acidosis correction on, in chronic HD patients, 37
  hyponatremia and "beer potomania" in non-beer drinkers, 1028-1031
  hypotension on chronic HD and, 814
  IGF-I and -II effects on tubular absorption of, 908
  renal DA system and balance of, 2:xliii-xlv
  urinary excretion of, *see* Urinary excretion, Na
National survey, Belgian, of pregnant ESRD patients on HD, 756-765, 863-864
Natriuretic peptides, *see* Atrial natriuretic peptides
Natural history of IgAN, 964-965
NE (nephropathia epidemica), prednisolone for severe thrombocytopenia in, 116-120
Necrotizing glomerulonephritis (GN), crescentic, MPO-ANCA-positive tubulointerstitial nephritis and, with renal eosinophilic infiltration and peripheral blood eosinophilia, 1032-1037
Nefazodone, adverse drug reactions between CsA and, 320-323
Neonatal tolerance to transplantation, 202-203
Neoplasm, *see* Malignancy
Nephrectomy, unilateral and subtotal, IGF-I and renal growth with, 908-909
Nephritis
  anti-glomerular basement membrane, with DN, 127-130
  see also specific types of nephritis; for example: Glomerulonephritis; Interstitial nephritis
Nephrology nurse practitioners in collaborative care model, 786-793
Nephropathia epidemica (NE), prednisolone for severe thrombocytopenia in, 116-120
Nephrosclerosis, *see* Hypertensive nephrosclerosis
Nephrosis, PA, lovastatin effects on glomerular macrophage influx and MCP-1 mRNA expression in, 190-194
Nephrotic syndrome (NS)
  in adolescents, 155-160
  in children, long-term moderate dose CsA for, 932-939
  in HIV-infected diabetic patients, 375-377
  IGF-I and IGF-BPs in, 915
  MMF for, 213-217
  postpartum, 723-728
  as primary diagnosis, renal transplantation and, 510, S1:35
Nephrotoxic acute renal failure (ARF), fenoldopam effects in, 752

Nephrotoxicity
of AmB, 780-785
of dexamethasone, 443-452
of FK506, acute allograft rejection and, S1:15-18
of IFN-α, 121-126
post-transplant nephrotoxic drug use concomitant with CsA therapy, 283-292; *see also* Cyclosporin A; Cyclosporine
Neural network, artificial, prediction of equilibrated postdialysis BUN by, in high-flux HD, 638-646
Neuropeptide Y (NPY), volume-induced HTN on HD and, 803-808
Neutralization of chemokines, 1075-1078
studies of, 1075-1076
therapeutic possibilities opened by, 1077-1078
Neutrophils, *see* Polymorphonuclear cell(s); Polymorphonuclear cell elastase
NF-κB (nuclear factor-κB), angiotensin II and, 173-174
NIDDM, *see* Non-insulin-dependent diabetes mellitus
Nightly intermittent peritoneal dialysis (NIPD), PMO differentiation and cytokine production in CCPD and, 234-241
Nitric oxide (NO), acute hypotension in chronic HD and enhanced production of, 809-817
Nitrogen, *see* BUN in ESRD
N-myc gene in renal development, 391
NO (nitric oxide), acute hypotension in chronic HD and enhanced production of, 809-817
Non-beer drinkers, "beer potomania" in, hyponatremia and, 1028-1031
Noncompliance, as barrier to HD adequacy, 593-601
Nondiabetic chronic nephropathy, strategies to retard progression of, 162-164
Nondiabetic end-stage renal disease (ESRD), elderly patients with, on CAPD, 479-490
Non-insulin-dependent diabetes mellitus (NIDDM)
apolipoprotein E4 reducing risk of DN with, 666-673
familial lobular glomerulopathy in, 6:E3
monoclonal gammopathy in, 1058-1064
Nonpositional malfunction of CVCs, low-dose urokinase to restore, 843
Nonreferral to nephrologist for ESRD, 399-400
Noradrenaline
NPY, volume-induced HTN on HD and, 803-808
plasma, in DN, 44-46
Normal subjects, IGF-I effects on glomerular hemodynamics in, 905
Normalized protein catabolic rate, IDWG and, 831, 832
Normoalbuminuria, risk of DN and, 670
NPY (neuropeptide Y), volume-induced HTN on HD and, 803-808
NS, *see* Nephrotic syndrome
Nuclear factor-κB (NF-κB), angiotensin II and expression of, 173-174
Nuclear receptor-mediated actions of calcitriol, 731-734, 736-737
Nurse practitioners, nephrology, in collaborative care model, 786-793
Nutrition
compensatory renal growth, IGF system and, 909
effects of, on IGF-I, 904
see also Nutritional status of ESRD patients on CAPD and/or HD *and entries beginning with term*: Dietary
Nutritional status of ESRD patients on CAPD and/or HD
high- and low-flux HD effects, compared, 491-494
IGF-I effects on, 912
ILGW and, 830-834
metabolic acidosis and, 884-889
as predictor of mortality in HD patients, 997-1006
see also Malnutrition in ESRD patients on CAPD, HD, and/or PD

O_2 (oxygen), stationary cycling effects on uptake of, during HD for ESRD, 631-637
Occult gastroparesis, effects of treatment of, on malnutrition of HD and PD patients, 62-66
1,25-$(OH)_2D_3$, *see* Calcitriol
25-OHD (25-hydroxyvitamin D), rickets and, 369, 370, 372, 373
OKT3, *see* Clinical trials of acute kidney transplant rejection
Oligloclonal expansion of intrarenal T cells in SLE, 418-426
OLT (orthotopic liver transplantation) for PSC complicated by anuric ARF, 360-363
On-line urea monitoring
with Biostat 1000 dialysate-based and Daugirdas blood-based methods, 1011-1018
in high-flux HDF patient, 74-80
IDWG and, 830-834
see also Kt/V on HD
Oral fenoldopam, effects of, 748-750
Organ transplant tolerance, *see* Long-term organ transplant tolerance
Orthostatic hypotension, effects of, on urine volume and Na excretion in DN, 41-48
Orthotopic liver transplantation (OLT) for PSC complicated by anuric ARF, 360-363
Osmolality, effects of sterilization process of CAPD fluids, glucose concentration and, on PMN functions and cytokine production by PBMCs, 273-281
Osteitis fibrosa, rickets versus, 373-374
Osteoblasts, calcitriol effects on, 729-742
Osteopontin in interstitial inflammation, 1078-1079
Outcomes
of acute kidney transplant rejection, S1:38
of cerebral hemorrhage and cerebrovascular disease in chronic HD patients, 991-996
with different RRTs, compared, 473-478
of liver transplant trials, S1:9-11
of long-term CsA therapy of NS in children, 934-935
of metabolic acidosis in ESRD, 888
of pancreas transplantation for IDDM with ESRD, 798-799
of pregnancy in HD or CAPD patients, 760-761, 767, 769, 771
of renal transplantation in mentally retarded recipients, 511
see also Mortality; Patient survival; Prognosis *and specific conditions*
Overdose, ciprofloxacin, ARF induced by, 710-712
Oxygen (O_2), stationary cycling effects on uptake of, during HD for ESRD, 631-637

P (phosphorus) in ESRD patients on HD, 621
serum, serum Ca × PO_4 product and, associated with mortality risk on chronic HD, 607-617
PA (puromycin aminonucleoside) nephrosis, lovastatin effects on glomerular macrophage influx and MCP-1 mRNA expression in, 190-194
PAI-1 (plasminogen activating inhibitor-1), angiotensin II and expression of, 173
Pancreas transplantation for IDDM with ESRD, cost-effectiveness of, 794-802
Paramesangial deposits, glomerular, associated with hypocomplementemia in MPGN types I and III, 427-434
Parathyroid hormone (PTH)
elevated serum P in chronic HD ESRD patients and, 607-617
intact, *see* Intact parathyroid hormone
plasma, Ca ketoglutarate and Ca carbonate effects on, 260
Partial spent dialysate collection method, SRI for urea determined by, 986-990
Pathophysiology and pathology
atlas of renal, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
of lupus nephritis and ANCA-associated systemic vasculitis, 5:l-lii
of renal DA system, 2:xlv
see also specific conditions
Patient acuity measurements, 818-829, 5:E5
Patient attitudes toward dialysis discontinuation, 872-873
Patient classification system (PCS) for chronic HD patients, 818-829, 5:E5
Patient/family wishes, and patient selection for dialysis, 12-18
Patient selection
for CVVHD, 227-233
for dialysis, 12-18, 131-132
Patient survival
with ARF and MOF, 229
with aspergillosis, 784
of nondiabetic elderly ESRD patients on CAPD, 481
on RRT, risk groups and, 475
of transplant recipients, tolerance and, 198
Pax-2 gene in renal development, 386, 387
PBMCs, *see* Peripheral blood mononuclear cells
PC (pseudotumor cerebri), as complication of brachiocephalic vein catheter thrombosis, 5:E3
PCPs, *see* Primary care physicians
PCS (patient classification system) for chronic HD patients, 818-829, 5:E5
PD, *see* Peritoneal dialysis
PDF (postdialysis fatigue), TNF-α role in, 1007-1010
PDGF (platelet-derived growth factor) B in renal development, 386, 390
PDGFRβ (platelet-derived growth factor receptorβ) in renal development, 386, 390
PEEP (positive end-expiratory pressure), fenoldopam effects on, 750
Peptides, *see* Atrial natriuretic peptides; Neuropeptide Y
Perceptions of nephrologist's role by ESRD patients, 577
Percutaneous renal biopsy of renal capsular artery pseudoaneurysm, 533-535
Percutaneous transluminal renal angioplasty (PTRA) for transplant RAS, 146
Peripheral blood eosinophilia, renal eosinophilic infiltration and, MPO-ANCA–positive tubulointerstitial nephritis and necrotizing crescentic GN with, 1032-1037
Peripheral blood mononuclear cells (PBMCs)
effects of osmolality, sterilization process of CAPD fluids, and glucose concentration on cytokine production by, 273-281
in SLE, TCR V_β in, 418-426
Peritoneal dialysis (PD)
HCV infection in renal transplant candidates on, 920-927
see also Continuous ambulatory peritoneal dialysis; Continuous cycling peritoneal dialysis; Nightly intermittent peritoneal dialysis; Peritoneal dialysis for ESRD
Peritoneal dialysis (PD) for ESRD, 62-73
effects of, on soluble L-selectin and leukocyte Mac-1, 67-73
malnutrition on, effects of occult gastroparesis treatment on, 62-66
testosterone replacement and vacuum tumescence therapy for impotence in patients on, 313-319
see also Continuous ambulatory peritoneal dialysis for ESRD
Peritoneal equilibration test, 495-501
Peritoneal monocytes/macrophages (PMOs), cytokine production and differentiation of, in NIPD and CCPD, 234-241
Peritonitis and CAPD for ESRD
in nondiabetic elderly patients, 481-483
in pregnant women, 769
Permanent central venous catheters (CVCs), HD, high-dose intradialytic urokinase to restore patency of, 841-847
Permanent vascular access placement, referral to nephrologist and, 405-406
Permeability defect with HCO_3 leak in immune-related dRTA, 527-532
Phosphate
in ESRD, *see* Phosphate in ESRD patients on CAPD and/or HD
IGF-I and -II effects on tubular absorption of, 907-908
in rickets, 373
serum Ca × $P0_4$ product and serum P associated with mortality risk on chronic HD, 607-617
Phosphate in ESRD patients on CAPD and/or HD
Ca × P_i in cerebrovascular events in, 994
in elderly patients, 484
at initiation of HD, 403
with RLS, 326
see also Phosphate in ESRD patients on chronic HD; Serum phosphate in ESRD
Phosphate in ESRD patients on chronic HD
phosphate-binding capacity of Ca ketoglutarate and Ca carbonate on chronic HD, 257-262
serum, 95, 607-617
Phosphorus, *see* P in ESRD patients on HD
Pilot treatment with FK506, S1:8
Pittsburgh University trials with FK506, S1:9-10
PKD, *see* Polycystic kidney disease
PKD1 gene, *TSC2* gene and, in contiguous gene syndrome, 1038-1043
Plasma adrenaline in DN, 44-46
Plasma anaritide in RCIN, 677

Plasma atrial natriuretic peptides (ANPs), effects of orthostatic hypotension on, in DN, 41-48
Plasma cell dyscrasia, extramedullary manifestations of, rheumatoid arthritis, erythema elevatum diutinum, POEMS syndrome, steroid-dependent DM and as, 4:E3
Plasma creatinine (Cr)
in gestational HTN, 310
in GN with MG, 352
in MLN, 682
in PKD, 57, 690
Plasma leptin, relationship of, to body composition of ESRD patients on HD, 655-661
Plasma noradrenaline in DN, 44-46
Plasma parathyroid hormone (PTH), Ca ketoglutarate and Ca carbonate effects on, 260
Plasma renin activity (PRA)
and acute kidney transplant rejection, S1:51-53, S1:55, S1:57
in DN, 44-46
Plasma total protein, soy protein and genistein effects on, 57
Plasma urea in PKD
soy protein effects on, 57
vitamin E effects and, 690
Plasma uric acid in gestational HTN, 310
Plasma vasopressin in DN, 44-46
Plasminogen activating inhibitor-1 (PAI-1), angiotensin II and expression of, 173
Plasminogen/plasmin system, angiotensin II and, 173
Platelet-derived growth factor (PDGF) B in renal development, 386, 390
Platelet(s) in postinfectious GN with TMA, 515
Platelet-derived growth factor receptorβ (PDGFRβ) in renal development, 386, 390
PMN, *see* Polymorphonuclear cell(s); Polymorphonuclear cell elastase
PMOs (peritoneal monocytes/macrophages), cytokine production and differentiation of, in NIPD and CCPD, 234-241
PO_4, *see* Phosphate
POEMs syndrome, steroid-dependent DM, erythema elevatum diutinum, and rheumatoid arthritis as extramedullary manifestations of plasma cell dyscrasia, 4:E3
Polycystic kidney disease (PKD)
as primary diagnosis, 185, 324, 481, 4:xlvi, 620, 992, S1:35
sex and effects of vitamin E on, 687-693
soy protein and genistein effects on progression of, 55-61
see also Autosomal dominant polycystic kidney disease
Polymorphism
apolipoprotein E4, and risk of DN with NIDDM, 666-673
see also Polymorphism, ACE gene
Polymorphism, ACE gene
in childhood IgAN, 774-779
I/D, DN and, 301-307
Polymorphonuclear cell(s) (PMN)
effects of sterilization process of CAPD fluids, glucose concentration, and osmolality on functions on, 273-281
see also Chemotactic factors, renal inflammation and
Polymorphonuclear cell (PMN) elastase, ANCAs to, enhancing elastase activity in systemic vasculitis, 978-985
Polyneuropathy, FAP type I, distribution and characterization of amyloid deposits in, 940-946
Portuguese type familial amyloid polyneuropathy (FAP type I), distribution and characterization of amyloid deposits in, 940-946
Positive end-expiratory pressure (PEEP), fenoldopam effects on, 750
Postdialysis BUN (blood urea nitrogen), prediction of equilibrated, by ANN, in high-flux HD, 638-646
Postdialysis fatigue (PDF), TNF-α role in, 1007-1010
Posthemodialysis weight, HH and, 626
Postinfectious glomerulonephritis (GN), 5:E1
TMA with, renal biopsy of, 513-520
Postpartum nephrotic syndrome (NS), 723-728
Potassium, *see* K
PRA, *see* Plasma renin activity
Practice guidelines on patient initiation to and withdrawal from dialysis, 874-875
Prealbumin in ESRD patients on chronic HD, IL-6, malnutrition and, 95
Prednisolone, severe thrombocytopenia and response to, in NE, 116-120
Preeclampsia, gestational HTN and, 308-312
Pregnancy
hypertensive, 308-312
postpartum NS, 723-728
see also Pregnancy in ESRD patients on CAPD and/or HD
Pregnancy in ESRD patients on CAPD and/or HD, 756-773
Belgian national survey of, on 756-765, 863-864
registry of, 766-773
Prehemodialysis weight
HH and, 626
IDWG and, 621
Prescription of HD for ESRD, as barrier to HD adequacy, 593-601
Prevalence
of HCV infection in renal transplant candidates, 922
of HGV and HCV infections in chronic HD patients, 218-226, 366-368
see also Incidence *and specific conditions*
Prevention
of IDDM progression to ESRD with ACEIs, 49-54
in primary care of ESRD patients, 577-580
prophylactic/therapeutic high-dose urokinase to restore CVC patency, 843-844
RCIN, with ANPs, 674-680
Primary care of ESRD patients, nephrologists as providers of, 574-583
effectiveness and cost of subspecialist-delivered care and, 575-576
nephrologists' role as primary care providers, 576-577
preventive care and cancer screening in, 577-580
primary care provider defined, 574
reimbursement issues in, and emergence of global capitation, 580-581
Primary care physicians (PCPs)
delayed referral to nephrologist and biases of, 402

see also Primary care of ESRD patients, nephrologists as providers of
Primary diagnosis, *see specific conditions*
Primary hyperaldosteronism, posttransplantation HTN due to, adrenal vein sampling in, 853-855
Primary mesangial injury, mesangiolysis due to, 560-563
Primary sclerosing cholangitis (PSC), anuric ARF complicating, OLT for, 360-363
Probucol, effects of, on serum lipoproteins and apolipoproteins in renal transplant recipients, 356-359
Prognosis
of ARF with dialysis, cost-effectiveness and, 546, 549
prognostic factors in idiopathic MN, 1-11
see also Outcomes *and specific conditions*
Program-provided system for general medical supplies, reducing CAPD and/or CCPD cost by switching from vendor-provided to, 662-665
Progression to ESRD
of chronic nephropathy, 161-170
see also Progression to ESRD, ACEIs and
Progression to ESRD, ACEIs and, 180-181
preventing, in IDDM, 49-54
retarding, 162, 165-167
Progression of renal disease
of early IgAN, risk factors for, 964-965
effects of dietary protein restriction on, 954-961, 1048-1049
IGF-I and, 910-911
of PKD, soy protein and genistein effects on, 55-61
see also Progression to ESRD *and specific conditions*
Prolactin in sexually dysfunctional ESRD males on HD or PD, 315
Proliferative forms of lupus nephritis, 6:E1
Proliferative glomerulonephritis (GN), as primary diagnosis, 929
Prophylaxis, *see* Prevention
Protein
binding, *see* Insulin-like growth factor-binding proteins
C-reactive, in ESRD patients on chronic HD, IL-6, malnutrition and, 95
in elderly nondiabetic ESRD patients on CAPD, 484
see also Dietary protein; Protein, urinary excretion of; Protein-7; Protein catabolic rate; Total protein
Protein, urinary excretion of
in ATS GN, 456, 457
in childhood IgAN, 774-779
see also Proteinuria
Protein-7, bone morphogenetic, in renal development, 386, 389-390
Protein catabolic rate
on HD, *see* Protein catabolic rate on HD
high-flux HDF and, 74-80
Protein catabolic rate on HD
on chronic HD, 37, 95
IDWG and, 830-834
Proteinuria
dexamethasone-induced, 443-452
in DN, 42, 303
in FAP type I, 941
in gestational HTN, 310
in GN, 352, 515
in idiopathic MN, 2, 3, 5-7
in IgAN, 965
in MLN, 682
in NIDDM, and risk of DN, 668, 670
and progression of chronic nephropathy, 162
see also Albuminuria; Protein, urinary excretion of
PSC (primary sclerosing cholangitis), anuric ARF complicating, OLT for, 360-363
Pseudoaneurysm
renal capsular artery, percutaneous renal biopsy of, 533-535
subclavian, compression of brachial plexus due to, from cannulation of jugular vein catheter, 694-697
Pseudotumor cerebri (PC), as complication of brachiocephalic vein catheter thrombosis, 5:E3
Psychological problems of nondiabetic elderly ESRD patients on CAPD, 485, 486
PTH, *see* Parathyroid hormone
iPTH, *see* Intact parathyroid hormone
PTRA (percutaneous transluminal renal angioplasty) for transplant RAS, 146
Pulmonary emboli, catheter-related, 845-846
Puromycin aminonucleoside (PA) nephrosis, lovastatin effects on glomerular macrophage influx and MCP-1 mRNA expression in, 190-194
Puumala virus in NE, 116-120
Pyelonephritis, as primary diagnosis, 4:xlvi, 510

Quality improvement, continuous, of HD for ESRD, HCFA report on, 584-592
Quality of life
of ARF patients, dialysis and, 547, 549
of nondiabetic elderly ESRD patients on CAPD, 486-487
and patient selection for dialysis, 12-18, 131-132
Questionnaire of Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation, reviewed, S1: 26-30

Race and ethnicity
albuminuria as predictor of diabetic retinopathy in Hispanics with NIDDM, 947-953
of CVVH and CVVHD patients, vancomycin clearance and, 1021
of idiopathic MN patients, 2, 4
of renal transplant recipients, *see* Race and ethnicity of renal transplant recipients
restricted dietary K effects and, 19-27
see also Race and ethnicity of ESRD patients on CAPD and/or HD
Race and ethnicity of ESRD patients on CAPD and/or HD, 587
BP control and, 620
chronic HD, 37, 610-612
compliance and, 103
HD adequacy and, 595, 597
hypertensive patients, 28-34
and nutritional status as predictor of mortality, 998, 1001
TB and, 849, 850
vascular access thrombosis and survival and, in AIDS patients, 250-256
and withdrawal and/or withholding of dialysis, 467

Race and ethnicity of renal transplant recipients
acute rejection and, S1:34, S1:51-53, S1:55, S1:57
drug use concomitant with CsA therapy and, 285
mentally retarded, 510
recurrent and de novo renal diseases and, 929
Radiation-induced mesangiolysis, 564-566
Radioactive iodine, ablation of TMNG with, in ESRD patient on HD, 698-700
Radiocontrast-induced nephropathy (RCIN), ANPs in prevention of, 674-680
Randomized clinical trials, *see* Clinical trials
Rapidly progressive glomerulonephritis (RPGN)
IgA ANCAs in, 341-344
as primary diagnosis, renal transplant rejection and, S1:35
rifampicin-associated, 112
RAS (renal artery stenosis) in renal transplantation, 142-148
RBF (renal blood flow), DA-1 agonist effects on, 743, 745, 746, 748-752
RCIN (radiocontrast-induced nephropathy), ANPs in prevention of, 674-680
Recirculation, *see* Access recirculation, HD
Recessive Alport's syndrome (AS), autosomal, molecular and immunohistochemical studies of, 6:E4
Recombinant human erythropoietin (rHuEPO) for ESRD patients on CAPD and/or HD
BP control and, 621
effects of, on male sexual dysfunction, 313, 314
in pregnant patients, 756-765, 769, 772
see also Iron in ESRD patients on HD and rHuEPO therapy
Recombinant human insulin-like growth factor-I, *see* Insulin-like growth factor-I
Recurrent focal segmental glomerulosclerosis (FSGS) following renal transplantation, 3:E3, 929
Recurrent mesangiolysis associated with mild mesangial and/or endothelial injury, 566-569
Recurrent renal diseases following renal transplantation, 3:E3, 928-931
Referral to nephrologist for ESRD, 398-417
delayed, 401-408
nonreferral, 399-400
and RRT initiation, *see* Timely initiation of RRT for ESRD
Registry of pregnancy in ESRD patients on HD and/or CAPD, 766-773
Rehabilitation of ESRD patients
of nondiabetic elderly patients, 479-490
referral to nephrologist and, 406-407
Reimbursement to nephrologists as primary care providers, 580-581
Rejection, *see* Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation
Renal angiotensin-converting enzyme (ACE), immunohistochemical localization of, in DN, 301-307
Renal artery graft, "true" mycotic aneurysm of, 1:E3
Renal artery stenosis (RAS) in renal transplantation, 142-148
Renal biopsy
in ARF with thrombocytopenia, fever, and anasarca, 890-895
of FAP type I, 940-946
percutaneous, of renal capsular artery pseudoaneurysm, 533-535
of postinfectious GN with TMA, 513-520
see also Renal biopsy, renal allograft rejection diagnosis and; Renal biopsy of IgAN; Renal biopsy of NS; Renal histology *and specific conditions*
Renal biopsy, renal allograft rejection diagnosis and, S1:15-25, S1:36
proposed consensus for definition of, S1:40-46
role of, in multicenter clinical trials, S1:19-25
Renal biopsy of IgAN
childhood IgAN, 774-779
of early IgAN, 964, 967
Renal biopsy of NS
in adolescents, 155-160
in HIV-infected patients, 375-377
of postpartum NS, 723-724
Renal blood flow (RBF), DA-1 agonist effects on, 743, 745, 746, 748-752
Renal capsular artery pseudoaneurysm, percutaneous renal biopsy of, 533-535
Renal disease
de novo, following renal transplantation, 928-931
with Down syndrome, 329-335
recurrent, following renal transplantation, 3:E3, 928-931
see also specific conditions
Renal dopamine (DA) system, Na balance and, 2:xliii-xlv
Renal effects of fenoldopam, 748-752
Renal eosinophilic infiltration, peripheral blood eosinophilia and, MPO-ANCA-positive tubulointerstitial nephritis and necrotizing crescentic GN with, 1032-1037
Renal failure
due to giant cell vasculitis, 1044-1047
due to infiltration by steroid-responsive IMT, 6:E5
and idiopathic MN, 1-11
mesangial IgG deposition and chronicity index as risk factors for HTN and, in early IgAN, 962-970
reversible, with hypereosinophilia during IFN-α therapy, 121-126
see also Acute renal failure; Chronic renal failure
Renal function
dexamethasone effects on, 445
dietary protein restriction effects on rate of decline of, 954-961, 1048-1049
in idiopathic MN, 7-8
IGF-I effects on, in CRF, 912-913
laboratory indices of, RRT initiation and, 408-410
recovery of, *see* Renal function recovery
residual, in nondiabetic elderly ESRD patients on CAPD, 485, 486
see also specific aspects of renal function
Renal function recovery
with CVVHD of ARF with MOF, 229-230
following acute kidney transplant rejection therapy, S1:47-59
Renal glutathione (GSH), vitamin E effects on, 687-693
Renal growth and development
IGF-I and IGF-II in compensatory, 908-911
see also Molecular renal development

Renal hemodynamics
DA-1 agonist effects on, 743-755
see also Glomerular hemodynamics; Renal blood flow
Renal histology
in ATS GN, 456-457
of familial lobular glomerulopathy, 6:E3
in idiopathic MN, 2, 4-5
see also Renal biopsy *and specific conditions*
Renal inflammation, *see* Chemotactic factors, renal inflammation and *and specific conditions*
Renal injury and lesions
endothelial injury, mesangiolysis and, 563-569
in IDDM, expression of integrin and type I collagen in SFs in, 293-300
macrophages in, 1:xlv-xlvii
see also Mesangial injury, mesangiolysis due to *and specific renal injuries*
Renal insulin-like growth factor system, *see* Insulin-like growth factor system
Renal replacement therapy (RRT)
outcomes of, compared, 473-478
see also Continuous renal replacement therapy; Hemodialysis; Peritoneal dialysis; Referral to nephrologist for ESRD; Renal transplantation
Renal services facilities, Pakistani, 4:xlv, 4:xlviii
Renal α-tocopherol (vitamin E), sex and effects of, on PKD, 687-693
Renal transplantation, 701-709
de novo renal diseases following, 928-931
FK506 trials in, S1:11
HCV infection in candidates for, 922-927
HTN following, due to primary hyperaldosteronism, adrenal vein sampling in, 853-855
immunosuppression and, *see* Immunosuppression
KS and lymphoma in, 706-709
laryngeal TB in, 701-705
liver/, microchimerism with, 199-200
mentally retarded recipients of, 509-512
in Pakistan, 4:xlvii-xlviii
probucol effects on hypercholesterolemia in, 356-359
RAS in, 142-148
recurrent renal diseases following, 3:E3, 928-931
see also Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation
Renal vascular resistance (RVR), DA-1 agonist effects on, 747, 749-751
Renin
DA receptor stimulation effects on, 745
see also Plasma renin activity
Renovascular disease, severe bilateral atherosclerotic, incidence of ESRD with medically treated, 971-977
Renovascular hypertension (HTN), Takayasu's arteritis and, 3:lix
Rescue, liver allograft, with FK506, S1:8
Residual renal function in nondiabetic elderly ESRD patients on CAPD, 485, 486
Resistance
to IGF-I in CRF, 912
steroid-resistant acute kidney transplant rejection, S1:42, S1:44, S1:45, S1:50
Resource scarcity, and patient selection for dialysis, 12-18, 131-132
Restless leg syndrome (RLS) in ESRD patients on HD, biochemical findings on, 324-328
Reticular aggregates with NS in adolescents, 155-160
Retinopathy, diabetic, albuminuria as predictor of, in Hispanics with NIDDM, 947-953
Reversal of kidney rejection, allograft biopsies as endpoints for, S1:22-23
Reverse transcriptase-polymerase chain reaction (RT-PCR)
of HCV in renal transplant candidates, 920-927
of HGV, 218-226
Reversible renal failure with hypereosinophilia during IFN-α therapy, 121-126
Rhabdomyolysis
in ESRD following surgery, 539-544
snake bite, and ARF, 6:xlviii-l
Rheumatoid arthritis, erythema elevatum diutinum, POEMS syndrome, steroid-dependent DM and, as extramedullary manifestations of plasma cell dyscrasia, 4:E3
Rheumatoid factor, IgMk, in cryoglobulin-induced GN, 435-442
rhIGF-I (recombinant human insulin-like growth factor-I), *see* Insulin-like growth factor-I
Ribonucleic acid, *see* RNA
Rickets, dietary Ca deficiency-induced, 369-374
Rifampicin, ARF associated with, 108-115
Risk factors
for cerebral hemorrhage and cerebrovascular disease in chronic HD patients, 991-996
of DN with NIDDM, apolipoprotein E4 polymorphism and, 666-673
for hypertensive ESRD, 28-34
mesangial IgG deposition and chronicity index as, for HTN and renal failure in early IgAN, 962-970
for progression of chronic nephropathy to ESRD, 162
for TB on HD, 850-851
see also specific risk factors
Risk stratification methods used in RRT outcome comparison, 473-478
RLS (restless leg syndrome) in ESRD patients on HD, biochemical findings on, 324-328
RNA (ribonucleic acid)
HGV, RT-PCR in identification of, 218-226
messenger, *see* mRNA
RPGN, *see* Rapidly progressive glomerulonephritis
RRT, *see* Renal replacement therapy
RT-PCR, *see* Reverse transcriptase-polymerase chain reaction
RVR (renal vascular resistance), DA-1 agonist effects on, 747, 749-751

Sarcoma, Kaposi's, lymphoma and, in renal transplant recipients, 706-709
SBP (systolic blood pressure), *see* Blood pressure
Sclerosing cholangitis, anuric ARF complicating primary, OLT for, 360-363
Sclerosis
tuberous, ADPKD and, 1038-1043
see also Glomerulosclerosis; Hypertensive nephrosclerosis

Screening of ESRD patients for cancer, 577-580
L-Selectin (CD62L), HD for CRF and, 67-73
Self-tolerance to transplantation, 201-202
Sequence analysis of type IV collagen genes in autosomal recessive AS, 6:E4
Sertraline hydrochloride for HH in ESRD, 624-630
Serum albumin
  dexamethasone effects on, 445
  in DN, ACE and, 303
  in ESRD, effects of delayed referral to nephrologist on, 403; *see also* Serum albumin in ESRD patients on HD
  in idiopathic MN, 3, 7
Serum albumin in ESRD patients on HD
  CAPD, and PD, effects of gastroparesis treatment on, 64
  on chronic HD, 95, 997-1006
  high- and low-flux HD effects on, 491-494
Serum apolipoproteins in renal transplant recipients, probucol effects on, 356-359
Serum Ca (calcium) in ESRD patients on HD, 95, 403
  serum Ca x PO_4 product associated with mortality risk on chronic HD, serum P and, 607-617
Serum cholesterol in NIDDM, and risk of DN, 668
Serum Cl (chloride) in ESRD patients on chronic HD, IL-6, malnutrition and, 95
Serum creatinine (Cr)
  in DN, ACE and, 303
  effects of delayed referral to nephrologist on, 403
  in ESRD patients on CAPD and/or HD, 64, 95
  in FAP type I, 941
  in GN, 456, 515
  in idiopathic MN, 3, 7
  in NIDDM, 949
  in RCIN, 677
Serum creatinine (Cr) in acute kidney transplant rejection
  in Efficacy Endpoints database, S1:38
  proposed consensus on definitions for, S1:40-46
  and response to acute rejection therapy, S1:53, S1:55, S1:57
Serum glucose, dexamethasone effects on, 445
Serum glutamate pyruvate transaminase, *see* Alanine aminotransferase
Serum glutamic-oxaloacetic transaminase (SGOT; aspartate aminotransferase) in gestational HTN, 310
Serum HCO_3 (bicarbonate) in ESRD, 403, 885, 888
Serum insulin-like growth factor-I (IGF-I), renal growth and, 908
Serum K (potassium) in chronic HD patients, IL-6, malnutrition and, 95
Serum lipoproteins in renal transplant recipients, probucol effects on, 356-359
Serum P (phosphorus), serum Ca $\times$ PO_4 product and, associated with mortality risk on chronic HD, 607-617
Serum phosphate in ESRD
  in chronic HD patients, 95, 607-617
  effects of delayed referral to nephrologist on, 403
Severe bilateral atherosclerotic renovascular disease, medically treated, incidence of ESRD with, 971-977
Severe crescentic glomerulonephritis (GN), immune-complex deposits, 550-554
Severe thrombocytopenia, and response to prednisolone in NE, 116-120
Sex
  of AmB therapy patients, 781
  of bilateral atherosclerotic renovascular disease patients, 972, 974
  of brachial plexus compression patients, 696
  of childhood IgAN patients, 776
  of CVVH and CVVHD patients, vancomycin clearance and, 1021
  of DN patients, 42, 94, 303
  and effects of vitamin E on PKD, 687-693
  of FAP type I patients, 941
  of GN patients, 352, 515
  of idiopathic MN patients, 2, 3
  of NIDDM patients, 668, 670, 949, 950
  of NS patients, 933, 936
  of RCIN patients, 676
  of renal transplant recipients, *see* Sex of renal transplant recipients
  of rifampicin-associated ARF patients, 111-113
  see also Sex of ESRD patients on CAPD and/or HD
Sex of ESRD patients on CAPD and/or HD, 587
  BP control and, 620
  on chronic HD, 37, 604, 610-612, 811, 992
  compliance and, 103
  HD adequacy and, 595, 597
  HH and, 625
  hypertensive patients, 30, 31
  IDWG and, 831, 832
  male patients, sexual dysfunction in, 313-319
  of nondiabetic elderly patients on CAPD, 481
  nutritional status and, 492, 998, 1001
  plasma leptin levels and, 658-660
  and on rHuEPO therapy, iron dextran for, 837
  TB and, 850
  vascular access thrombosis and survival and, 251
  weekly Cr clearance and Kt/V_{urea} on CAPD and, 496
  and withdrawal of dialysis, 467
Sex hormone-binding globulin (SHBG) in sexually dysfunctional ESRD males on HD or PD, 315
Sex of renal transplant recipients
  acute rejection and, S1:34, S1:51-53, S1:55, S1:57
  de novo and recurrent renal diseases and, 929
  and drug use concomitant with CsA therapy, 285
  mentally retarded, 510
Sexual dysfunction in male ESRD patients on HD or PD, 313-319
SFs (skin fibroblasts) with renal lesions in IDDM, expression of integrin and type I collagen in, 293-300
SGA, *see* Subjective global assessment of malnutrition in ESRD
SGOT (serum glutamic-oxaloacetic transaminase; aspartate aminotransferase) in gestational HTN, 310
SGPT (serum glutamate pyruvate transaminase), *see* Alanine aminotransferase
SHBG (sex hormone-binding globulin) in sexually dysfunctional ESRD males on HD or PD, 315
Sialic acid in chronic HD patients, IL-6, malnutrition and, 95
Siblings, fibrillary GN in, 5:E4

Signal amplification assay, bDNA, of HCV infection in chronic HD patients, 647-654
Sjögren's syndrome, dRTA and, 527-532
Skin fibroblasts (SFs) with renal lesions in IDDM, expression of integrin and type I collagen in, 293-300
SLE, *see* Systemic lupus erythematosus
Sleeve thrombus (fibrin sleeve) around CVCs, 845
Smoking
  and bilateral atherosclerotic renovascular disease, 972, 974
  and hypertensive ESRD, 30, 31
  by NIDDM patients, and risk of DN, 668, 670
  and nutritional status as predictor of mortality in HD patients, 998, 1001
  and progression of chronic nephropathy, 162
  and TB in HD patients, 850
  see also Smoking by chronic HD patients
Smoking by chronic HD patients
  elevated serum P and serum Ca × PO_4 product and, 610-612
  and heart rate variability, 602-606
Snake bite
  Habu, mesangiolysis due to venom nephropathy of, 560-562
  rhabdomyolysis and, and ARF, 6:xlviii-l
Sodium, *see* Na
Solid organ transplantation, *see* Bone marrow/solid organ transplantation; Liver transplantation; Renal transplantation
Soluble L-selectin, HD for CRF and, 67-73
Solute clearance
  high-fill volumes optimizing, 1050-1058
  see also Endogenous solute clearance
Solute removal index (SRI) for urea determined by partial spent dialysate collection method, 986-990
Soy protein, effects of, on PKD progression, 55-61
Splenic hemorrhage, spontaneous, with Wegener's granulomatosis, 860-862
Splenic vasculitis, hemorrhages due to, in Wegener's granulomatosis, 860-862
Spontaneous splenic hemorrhage with Wegener's granulomatosis, 860-862
SRI (solute removal index) for urea determined by partial spent dialysate collection method, 986-990
Staffing requirements, PCS and, 818-829, 5:E5
Stationary cycling, CV response to, during HD, 631-637
Stenosis, renal artery, in renal transplantation, 142-148
Sterilization of CAPD fluids, effects of glucose concentration, osmolality and, on PMN functions and cytokine production by PBMCs, 273-281
Steroids
  acute kidney transplant rejection resistant to, defined, S1:42, S1:44, S1:45, S1:50
  for MLN, 681-686
  renal failure due to infiltration by steroid-responsive IMT, 6:E5
  renal function recovery following acute rejection therapy with, S1:47-59
  severe thrombocytopenia and response to prednisolone in NE, 116-120
  steroid-dependent DM, POEMs syndrome, erythema elevatum diutinum, and rheumatoid arthritis as extramedullary manifestations of plasma cell dyscrasia, 4:E3
  vacuum tumescence and testosterone replacement therapy for impotence in ESRD patients on HD or PD, 313-319
Streptozotocin-induced diabetes mellitus, IGF system and compensatory renal growth in, 909
Stress, NPY activated by, 803-808
Subclavian pseudoaneurysm, compression of brachial plexus due to, from cannulation of jugular vein catheter, 694-697
Subclavian vein catheter, brachiocephalic vein thrombosis associated with, PC as complication of, 5:E3
Subjective global assessment (SGA) of malnutrition in ESRD
  in HD patients, 263-272, 3:E3
  in nondiabetic elderly patients on CAPD, 484-485
Subspecialist-delivered primary care, cost and effectiveness of, 575-576
Subtotal nephrectomy, IGF-I and renal growth with, 908-909
Successfully treated acute kidney transplant rejection, defined, S1:42, S1:44-45
Supply inventories during home visits measuring compliance with CCPD and CAPD, 101-107
Surgery
  in ESRD patients, rhabdomyolysis following, 539-544
  see also Nephrectomy; Transplantation
Survival, *see* Graft survival; Patient survival
Sympathetic activity, relation between heart rate variability and, with NO production on chronic HD, 809-817
Systemic lupus erythematosus (SLE)
  oligoclonal expansion of intrarenal T cells in, 418-426
  pathology of, 5:l-lii
  as primary diagnosis, renal transplant rejection and, S1:35
  see also Lupus nephritis
Systemic vasculitis, *see* Antineutrophil cytoplasmic antibodies, systemic vasculitis and
Systolic blood pressure, *see* Blood pressure

T cell(s), intrarenal, oligoclonal expansion of, in SLE, 418-426
T-cell receptor (TCR) V_β in SLE, 418-426
Tacrolimus, *see* FK506
Takayasu's arteritis, renovascular HTN and, 3:lix
TB, *see* Tuberculosis
TCR (T-cell receptor) V_β in SLE, 418-426
Temporal arteritis (giant cell vasculitis), renal failure in, 1044-1047
Testosterone replacement therapy, vacuum tumescence and, for impotence in ESRD patients on HD or PD, 313-319
TGF-β1, *see* Transforming growth factor-β1
Therapy
  potential, with vitamin-D related compounds, 738
  therapeutic possibilities derived from chemokine neutralization, 1077-1078
  see also specific treatment modalities; for example: Clinical trials; Drugs; Prevention; Renal replacement therapy *specific conditions and entries beginning with term*: Dietary

α3β1 (alpha3beta1) in renal development, 386, 390-391
Thrombocytopenia
  fever, anasarca, ARF and, 890-895
  with rifampicin-associated ARF, 111
  severe, and response to prednisolone in NE, 116-120
Thrombosis
  brachiocephalic vein, associated with subclavian vein catheters, PC as complication of, 5:E3
  see also Thrombosis, vascular access
Thrombosis, vascular access
  graft thrombosis and survival in AIDS nephropathy patients, race and, 250-256
  permanent CVC, 841-847
Thrombotic microangiopathy (TMA), 513-526
  with cryoglobulinemic MPGN and HCV infection, 521-526
  with postinfectious GN, renal biopsy of, 513-520
Thymectomy, GN, MG and, 350-355
Thymic transplant tolerance, 201-207
  acquired, 203-207
  link between mixed bone marrow chimeras and, 207
  neonatal, 202-203
  self-tolerance, 201-202
Thymoma, GN, MG and, 350-355
TIBC (total iron-binding capacity), transferrin and, and malnutrition in ESRD patients on HD, 263-272, 3:E3
Time, caregiver, required by chronic HD patients, 818-829, 5:E5
Time on chronic HD for ESRD
  cerebrovascular events and, 992
  elevated serum P and serum Ca × PO_4 product, 610
  heart rate variability and, 604
  hypotension and, 811
  malnutrition, IL-6 and, 95, 96
Time on HD and/or PD for ESRD
  on chronic HD, *see* Time on chronic HD for ESRD
  compliance and, 103
  HD adequacy and, 595, 597
  IDWG and, 831
  male sexual dysfunction and, 314-316
  nutritional status and, 95, 96, 265, 268, 492
  of pregnant women, 768
  TB and, 849, 850
  vascular access thrombosis and survival and, 251
  and withdrawal or withholding dialysis, 467
Timely initiation of RRT for ESRD, 408-415
  economic implications of, 415
  and laboratory indices of renal function, 408-410
  rationale for, 410-413
  traditional indications for dialysis initiation and, 408
  trends in, 413-414
TLC (total lymphocyte count), effects of metabolic acidosis correction on, in chronic HD patients, 35-40
TMA, *see* Thrombotic microangiopathy
TMNG (toxic multinodular goiter) in ESRD patient on HD, radioactive iodine ablation of, 698-700
TNF-α, *see* Tumor necrosis factor-α
α (alpha)-Tocopherol (vitamin E), renal, sex and effects of, on PKD, 687-693
Tolerance
  to Ca ketoglutarate and Ca carbonate, 260-261
  see also Long-term organ transplant tolerance
Total bilirubin in CVVH and CVVHD patients, vancomycin clearance and, 1021
Total cholesterol
  in chronic HD patients, IL-6, malnutrition and, 95
  in NIDDM, and risk of DN, 670
Total iron-binding capacity (TIBC), transferrin and, and malnutrition in ESRD patients on HD, 263-272, 2:E3
Total lymphocyte count (TLC), effects of metabolic acidosis correction on, in HD patients, 35-40
Total protein
  in DN, ACE and, 303
  in HD patients, malnutrition and, 95, 265, 268
  plasma, effects of soy protein and genistein on, 57
Toxic multinodular goiter (TMNG) in ESRD patient on HD, radioactive iodine ablation of, 698-700
Toxicity, *see* Nephrotoxicity; Snake bite
Tranexamic acid for GI bleeding due to colonic angiodysplasias in ESRD patients on HD, 536-538
Transferrin in ESRD patients on HD
  IDWG and, 831, 832
  with RLS, 326
  TIBC and, and malnutrition, 263-272, 3:E3
Transferrin saturation (TSAT) in ESRD patients on HD, 83, 265, 837
Transforming growth factor-β1 (TGF-β1)
  angiotensin II and expression of, 172-173
  effects of angiotensin II inhibitors on, in ATS GN, 453-463
Transluminal renal angioplasty, percutaneous, for transplant RAS, 146
Transplantation
  pancreas, for IDDM with ESRD, cost-effectiveness of, 794-802
  renal artery, "true" mycotic aneurysm in, 1:E3
  see also Liver transplantation; Long-term organ transplant tolerance; Renal transplantation
Transthyretin (TTR) in FAP type I, 940-946
Triglycerides
  in chronic HD patients, 95, 994
  in elderly nondiabetic ESRD patients on CAPD, 484
Trisomy 7 with MDS, MPO-ANCAs with, crescentic GN and, 336-340
Trisomy 21 (Down syndrome), renal disease with, 329-335
"True" mycotic aneurysm of renal artery graft, 1:E3
TSAT (transferrin saturation) in ESRD patients on HD, 83, 265, 837
TSC (tuberous sclerosis), ADPKD and, 1038-1043
TSC2 gene, PKD1 gene and, in contiguous gene syndrome, 1038-1043
TTR (transthyretin) in FAP type I, 940-946
Tuberculin skin test (TST) for HD patients, 848-852
Tuberculosis (TB)
  anergy and, in HD patients, 848-852
  laryngeal, in renal transplantation recipients, 701-705
  postpartum NS and, 723-728
Tuberous sclerosis (TSC), ADPKD and, 1038-1043
Tubular acidosis, permeability defect with HCO_3 leak and immune-related dRTA, 527-532

Tubular function, IGF-I and -II effects on, 907-908
Tubular glomerular distribution of amyloid deposits in FAP type I, 942-944
Tubular necrosis, *see* Acute tubular necrosis
Tubulointerstitial changes in idiopathic MN, 5
Tubulointerstitial fibrosis, angiotensin II and, 171-176
Tubulointerstitial nephritis
  MPO-ANCA-positive crescentic necrotizing GN and, with renal eosinophilic infiltration and peripheral blood eosinophilia, 1032-1037
  as primary diagnosis, acute kidney transplant rejection and, S1:35
Tumor(s), *see* Malignancy *and specific tumors*
Tumor markers in ESRD, 578-579
Tumor necrosis factor-α (TNF-α)
  angiotensin II and expression of, 174-175
  PBMC production of, effects of sterilization process of CAPD fluids, glucose concentration, and osmolality on, 273-281
  role of, in PDF, 1007-1010
Type I collagen, expression of integrin and, in SFs with renal lesions in IDDM, 293-300
Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
Type I familial amyloid polyneuropathy (FAP), distribution and characterization of amyloid deposits in, 940-946
Type I membranoproliferative glomerulonephritis (MPGN), glomerular paramesangial deposits associated with, 427-434
Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
Type III membranoproliferative glomerulonephritis (MPGN), glomerular paramesangial deposits associated with, 427-434
Type IV collagen gene mutations in autosomal recessive AS, 6:E4

Ultrafiltration, HTN control and, 621
Ultrasound, echocardiography of heart rate variability in ESRD patients on chronic HD, 602-606
Ultrasound dilution, blood flow and recirculation with internal jugular vein TwinCath measured with, 87-92
Unilateral nephrectomy, IGF-I and renal growth with, 908
Urea
  Ca ketoglutarate and Ca carbonate effects on, 260
  effects of delayed referral to nephrologist on, 403
  in ESRD patients, *see* Urea in ESRD patients on HD
  SRI for, determined by partial spent dialysate collection method, 986-990
  see also Plasma urea in PKD *and entries beginning with term*: Urea
Urea in ESRD patients on HD
  or PD, in sexually dysfunctional males, 315, 316
  with RLS, 326
  see also BUN in ESRD patients on HD; On-line urea monitoring; Urea reduction ratio on HD
Urea kinetic modeling, postdialysis BUN with ANN and, compared, 638-646
Urea rebound in ESRD patients on high-flux HD, 638-646
Urea reduction ratio (URR) on HD
  HCFA report on, 584-592
  HD adequacy and, 135-141; *see also* Adequacy of HD for ESRD
  HH and, 626
  IDWG and, 831, 832
  TB and, 850
  TIBC, malnutrition and, 265, 268
Uremia, *see* Chronic renal failure; End-stage renal disease; Hemolytic uremic syndrome
Uremic syndrome, *see* Hemolytic uremic syndrome
Uric acid, plasma, in gestational HTN, 310
Urinary excretion
  glucose, in DN, 44-46
  in idiopathic MN, *see* Urinary excretion in idiopathic MN
  K, furosemide effects on, dRTA, 530
  Na, *see* Urinary excretion, Na
  protein, *see* Protein, urinary excretion of
  TGF-β1, in ATS GN, 456, 457
  see also entries ending with suffix: -uria
Urinary excretion, Na
  DA receptor stimulation effects on, 745
  DA in regulation of, 2:xliii
  furosemide effects on, dRTA, 530
  orthostatic hypotension in DN and, 41-48
  restricted dietary K effects on, 19-27
Urinary excretion in idiopathic MN
  C3dg and C5b-9, 3, 7
  IgG, 2, 3, 6
  β_2-microglobulin, 2, 3, 6-7
Urine volume in DN, effects of orthostatic hypotension on, 41-48
Urokinase, high-dose intradialytic, to restore patency of permanent HD CVCs, 841-847
URR, *see* Urea reduction ratio on HD
U.S. trials with FK506, S1:10-11

Vacuum tumescence therapy, testosterone replacement and, for impotence in ESRD patients on HD or PD, 313-319
Vancomycin, clearance of, by CVVHD and CVVH, 1019-1027
Variability, heart rate, on chronic HD, 602-606
  relationship between sympathetic activity and, NO production and, 809-817
Vascular access, HD
  permanent vascular access placement and early referral to nephrologist, 405-406
  thrombosis of, *see* Thrombosis, vascular access
  type of, as barrier to HD adequacy, 593-601
  see also Access recirculation, HD; Catheters, HD
Vascular interstitial glomerular distribution of amyloid deposits in FAP type I, 943, 944
Vascular resistance, renal, DA-1 agonist effects on, 747, 749-751
Vasculitis
  giant cell, renal failure in, 1044-1047
  systemic, *see* Antineutrophil cytoplasmic antibodies, systemic vasculitis and
Vasopressin (antidiuretic hormone)
  DA receptor stimulation effects on, 745
  plasma, in DN, 44-46

Vendor-provided system for general medical supplies, switching from, to program-provided system to reduce CAPD and/or CCPD cost, 662-665
Venom, *see* Snake bite
Venous line blood flow, access flow measurement and, 504-506
Venovenous hemodialysis, *see* Continuous venovenous hemodialysis
Venovenous hemofiltration, continuous, vancomycin clearance by, 1019-1027
Vitamin D metabolites, *see specific vitamin D metabolites*
Vitamin E (α-tocopherol), renal, sex and effects of, on PKD, 687-693
Volume-induced hypertension (HTN) on HD, NPY and, 803-808
Water
  accidental hypothermia of immersion into cold, ARF and, 856-859
  IGF-I and -II effects on tubular absorption of, 908
Weekly creatinine (Cr) clearance, Kt/V_{urea} and, on CAPD, 495-501
Wegener's granulomatosis, ANCAs in
  ANCAs to PMN elastase in, 978-985
  with spontaneous splenic hemorrhage, 860-862
Weight, *see* Body weight
White Americans, *see* Race and ethnicity
Withholding and/or withdrawal of dialysis, 464-472
  see also Dialysis discontinuation
Wnt-4 gene in renal development, 386, 388
WT-1 gene in renal development, 386-387